A sensitive and affordable multiplex RT-qPCR assay for SARS-CoV-2 detection

Martin A.M. Reijns[1,*], Louise Thompson[2], Juan Carlos Acosta[3], Holly A. Black[2,4], Francisco J. Sanchez-Luque[1,5], Austin Diamond[2], David A. Parry[1], Alison Daniels[6], Marie O'Shea[7], Carolina Uggenti[4], Maria C. Sanchez[6], Alan O'Callaghan[1], Michelle L.L. McNab[6], Martyna Adamowicz[4], Elias T. Friman[1], Toby Hurd[1], Edward J. Jarman[1], Frederic Li Mow Chee[3], Jacqueline K. Rainger[1], Marion Walker[3], Camilla Drake[1], Dasa Longman[1], Christine Mordstein[1,8], Sophie J. Warlow[4], Stewart McKay[1], Louise Slater[2], Morad Ansari[2], Ian P.M. Tomlinson[3], David Moore[2], Nadine Wilkinson[9], Jill Shepherd[9], Kate Templeton[9], Ingolfur Johannessen[9], Christine Tait-Burkard[7], Jürgen G. Haas[6], Nick Gilbert[1], Ian R. Adams[1], Andrew P. Jackson[1]

1. MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh, Edinburgh, UK

2. NHS Lothian, The South East of Scotland Clinical Genetic Service, Western General Hospital, Edinburgh, UK

3. Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh, Edinburgh, UK

4. Centre for Genomic & Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh, Edinburgh, UK

5. Centre Pfizer-University of Granada-Andalusian Government for Genomics and Oncological Research (Genyo), Granada, Spain

6. Division of Infection Medicine, Edinburgh Medical School, The University of Edinburgh, Edinburgh, UK

7. The Roslin Institute and Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Edinburgh, UK

8. The Milner Centre for Evolution, Department of Biology and Biochemistry, University of Bath, Bath, UK

9. NHS Lothian, Medical Microbiology and Virology Service, Royal Infirmary of Edinburgh, Edinburgh UK

* Correspondence to MAMR, martin.reijns@igmm.ed.ac.uk

Abstract

With the ongoing COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, there is need for sensitive, specific and affordable diagnostic tests to identify infected individuals, not all of whom are symptomatic. The most sensitive test involves the detection of viral RNA using RT-qPCR, with many commercial kits now available for this purpose. However, these are expensive and supply of such kits in sufficient numbers cannot always be guaranteed. We therefore developed a multiplex assay using well-established SARS-CoV-2 targets alongside a human cellular control (*RPP30*) and a viral spike-in control (PhHV-1), which monitor sample quality and nucleic acid extraction efficiency respectively. Here, we establish that this test performs as well as widely used commercial assays, but at substantially reduced cost. Furthermore, we demonstrate >1,000-fold variability in material routinely collected by nose-and-throat swabbing, and establish a statistically significant correlation between the detected level of human and SARS-CoV-2 nucleic acids. The inclusion of the human control probe in our assay therefore provides a quantitative measure of sample quality that could help reduce false negative rates. We demonstrate feasibility of establishing a robust RT-qPCR assay at ~10% of the cost of equivalent commercial assays, which could benefit low resource environments and make high volume testing more affordable.

Introduction

The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2 [1], originated in Wuhan (China) in December 2019 and rapidly spread across the globe, resulting in substantial mortality [2, 3] and widespread economic damage. Until a vaccine becomes available, public health strategies centred on reducing the rate of transmission are crucial to mitigating the epidemic, for which effective and affordable testing strategies to enable widespread population surveillance are essential. The most sensitive test to diagnose infected individuals involves the detection of SARS-CoV-2 viral RNA using RT-qPCR, most commonly using samples collected with nasopharyngeal (nose-and-throat) swabs (NTS), although there is increasing evidence that the use of saliva may be a valid alternative [4-7]. Many commercial kits are now available, most of which employ multiplex RT-qPCR, detecting 2 or 3 different SARS-CoV-2 targets, and generally include an internal control to show successful nucleic acid extraction. However, such kits are often costly and their supply in sufficient numbers cannot always be guaranteed. We therefore developed a similar multiplex assay using well-established SARS-CoV-2 targets and internal controls, which can be carried out at a significantly lower cost and provides more flexibility to ensure resilience against potential shortages in reagent supplies.

Our assay makes use of the Takara One Step PrimeScript III RT-qPCR kit. This reagent was used in the first high profile publication to describe SARS-CoV-2 [1], and it has since been shown to outperform a number of similar reagents [8]. Before commercial COVID-19 assays were available, various in-house assays were published on the WHO website [9]. Based on the data available at the time (March 2020), we decided to focus our initial efforts on targeting the following SARS-CoV-2 genes (Fig 1A; [10-12]): E (envelope), RdRp (RNA-dependent RNA polymerase) and N (nucleocapsid). Corman et al (2020) proposed the E gene as a useful target for first line screening, with the RdRp gene suggested as a good target for confirmatory/discriminatory assays [13, 14]. The N gene was central to the USA Centers for Disease Control and Prevention (CDC) in vitro diagnostics emergency protocol, with

42 three different primer/probe sets (N1, N2 and N3) used against different portions of this viral gene
43 [9]. The CDC protocol also included a probe against human *RPP30*, a single copy gene encoding the
44 protein subunit p30 of the Ribonuclease (RNase) P particle, to ensure the presence of a sufficient
45 number of cells in patient samples and successful isolation of intact nucleic acids.

46 In early versions of these protocols, all probes were labelled with fluorescein amidite (FAM), and
47 separate reactions were therefore needed to detect each target. To increase efficiency, we
48 developed a multiplex assay using 4 different fluorescent labels (FAM, HEX, CAL Fluor Red 610 and
49 Quasar 670) for each of the probes, allowing their detection in a single reaction. In the final version
50 of our assay, we use previously described primers and probes against the well-established SARS-CoV-
51 2 E and N gene (N1 and N2) targets, as well as a human cellular control and a viral spike-in control
52 (Fig 1B, C): human *RPP30* and Phocine Herpes Virus 1 (PhHV-1, hereafter referred to as PhHV). The
53 rationale behind the human control is that a considerable number of patients with clinical and
54 radiological signs of COVID-19 are PCR negative; and poor quality of swab samples with no or little
55 usable patient material is one possible explanation for this [15]. In essence, the *RPP30* control
56 provides a measure of sample quality. In addition, a defined amount of PhHV is spiked into each
57 sample with the lysis buffer at the start of the nucleic acid isolation procedure, resulting in a known
58 cycle quantification or Cq value (also referred to as the cycle threshold or Ct value, [16]). Detection
59 of PhHV (using the Glycoprotein B gene as a target) simultaneously controls for extraction and
60 amplification efficiency, and indicates absence of PCR inhibitors [17, 18].

61 If paired with an in-house RNA extraction protocol, our assay can be performed for less than £2
62 (GBP; $2.50, USD) per test, excluding cost of plastic consumables, which could mean a potential 10-
63 fold difference in cost compared to commercial kits. Here we present data that demonstrates
64 equivalent performance to the commercial TaqPath COVID-19 Combo Kit (CE-IVD; Thermo Fisher
65 Scientific) and Abbott RealTime SARS-CoV-2 assay. We also document the utility of inclusion of
66 *RPP30* as a human internal control to provide important sample quality information.

67

68 ## Results

69 **N and E gene multiplex assays sensitively detect viral RNA**

70 With the aim of developing a sensitive and affordable assay for the detection of SARS-CoV-2 RNA,
71 we tested three different 4-plex strategies (Fig 1B, C). All made use of *RPP30* (HEX) and PhHV (Cy5)
72 probes employed as internal controls (controlling for the presence of human cells in patient samples,
73 and successful nucleic acid isolation, respectively), as well as a CFR-labelled (CAL Fluor Red 610)
74 probe for the SARS-CoV-2 E gene. To enhance assay sensitivity and specificity, a FAM-labelled probe
75 against a second SARS-CoV-2 target was included in each of the three assays: RdRp, N1 or N2 (N
76 gene). We named these tests RdE-RP (RdRp, E, RPP30, PhHV), N1E-RP (N1, E, RPP30, PhHV) and N2E-
77 RP (N2, E, RPP30, PhHV) respectively (Fig 1C). Initial validation tests showed that these assays were
78 capable of detecting cultured SARS-CoV-2, with Cq values for E, N1 and N2 similar to those for
79 ORF1ab, S and N gene obtained using the ThermoFisher TaqPath COVID-19 assay. In contrast, RdRp
80 Cq values were substantially higher (Fig 1D; 4.4-6.1 cycles above the other targets).

81 Next, the RdE-RP, N1E-RP and N2E-RP assays were used to test SARS-CoV-2 positive and negative
82 patient samples (n = 19), comparing them to the commercial TaqPath assay and Abbott RealTime
83 SARS-CoV-2 assay (which detects RdRp and N gene). The N1E-RP and N2E-RP assays both correctly
84 identified all 9 samples that had tested positive using the TaqPath and Abbott assays (Table 1). The
85 RdE-RP assay performed less well, identifying 7 of these samples correctly, giving inconclusive results
86 for the other two (P18 and 19), with E gene but not RdRp detected. Overall, we find RdRp detection
87 to be at least 20-fold less sensitive than for E gene, N1 and N2 under our assay conditions; consistent
88 with reports by others [19]. This may be due to a mismatch in the reverse primer employed in the
89 RdRp (P2) assay, as originally designed [14]. Both N1E-RP and N2E-RP assays also identified positive
90 samples that scored negative with the commercial tests, suggesting potentially higher sensitivity of
91 our assays. Of the 10 patient samples that were negative for the Abbott assay, 9 were similarly

92 shown to be negative using the N1E-RP assay, whereas 8 of these were negative for the N2E-RP
93 assay. Patient 11, previously negative using the Abbott assay, was inconclusive with TaqPath (1 of 3
94 SARS-CoV-2 targets detected) and N2E-RP assays (1 of 2 targets detected), but positive in the N1E-RP
95 assay. Patient 12 had previously tested negative using both Abbott and TaqPath assays, and was also
96 negative for N1E-RP; however, this sample tested weakly positive for both SARS-CoV-2 targets in the
97 N2E-RP assay. Cq values were high for both P11 and P12, close to the limit of detection, but with
98 multiple viral targets detected, these likely represent true positives. However, differentiating
99 between samples with low viral loads and false positives is challenging. Analysis of such samples by
100 Sanger sequencing of PCR products, or nanopore sequencing of RNA present could provide useful
101 information. Further clinical evaluation and repeat sampling of the patient involved may also be a
102 beneficial route to a secure clinical diagnosis.

103 As our initial characterisation demonstrated the N1E-RP and N2E-RP assays to be at least as sensitive
104 as two commercial assays, TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific) and Abbott
105 RealTime SARS-CoV-2 (Abbott Laboratories), we focussed on these two assays for further validation
106 experiments.

107

108 **Multiplex assays for N and E genes can detect between 1 and 50 copies of IVT RNA**

109 To determine the detection limit for the N1E-RP and N2E-RP assays, in vitro transcribed (IVT) RNA
110 controls for each of the SARS-CoV-2 targets were prepared. An equimolar mix was used to make a
111 dilution series (for 10,000 down to 1 copy of RNA per reaction; a 50-copy control was also included)
112 and Cq values determined in triplicate using both assays (Fig 2A). To test our nucleic acid isolation
113 protocol, all dilutions after extraction were simultaneously tested in triplicate (Fig S1A). All probes
114 (E, N1 and N2) reproducibly detected 50 copies (Fig 2A, Fig S1A and Table S1). The N1 probe
115 detected 10 copies reproducibly (6 out of 6; 6/6), while the N2 probe did so in some reactions (4/6)
116 of the respective 4-plex assays. The E probe detected 10 copies reproducibly in the N2E-RP assay

117 (6/6), but only did so in half of the N1E-RP reactions (3/6). As might be expected, single copies of
118 RNA were only detected in a small proportion of reactions for each probe: E (2/12), N1 (3/6) and N2
119 (1/6). We therefore conclude that our assays have the sensitivity to detect between 1 and 50 copies
120 of IVT RNA (Fig 2A, Fig S1A and Table S1), both pre and post-extraction.

121

122 **N1E-RP and N2E-RP assays can detect between 1 and 3 copies of viral RNA**

123 To confirm the range of detection for total viral RNA, nucleic acids isolated from cultured SARS-CoV-
124 2 were used to make a dilution series (10^{-1} to 10^{-6}), and Cq values determined in triplicate using the
125 N1E-RP and N2E-RP assays (Fig 2B). To test the impact of the nucleic acid isolation procedure on
126 extraction of low copy numbers of viral RNA, and to test the PhHV spike in control, the dilution
127 series was also re-extracted and used for RT-qPCR simultaneously (Fig S1B). Sensitivity of detection
128 for these samples was highest for E gene, followed by N1 and N2 (Fig 2B, Fig S1B and Table S2).
129 Signal was lost for the 10^{-5} dilution in most cases, consistent with the Cq values of the undiluted
130 sample (21.3-23.4) and the 100,000-fold reduction in copy number for this dilution (theoretically
131 predicted Cq values, ~38-40). For all extractions and RT-qPCR replicates the signal for the PhHV spike
132 in was highly reproducible (Table S2), with a Cq value of 32.5 ± 0.40 (mean ± SD, range 30.7-33.0),
133 indicating robust extraction efficiency and absence of PCR inhibitors.

134 Finally, 8 quality control samples obtained from QCMD (an international external quality assessment
135 organisation) were also tested using the N1E-RP, N2E-RP and TaqPath assays. Each assay gave the
136 same outcome, consistent with data provided by QCMD (Table S3), identifying 5 samples as positive
137 (4 to 4,000 copies of SARS-CoV-2 per reaction) and 3 as negative (containing transport medium or
138 different corona viruses). All probes used in the N1E-RP and N2E-RP assays displayed a linear range
139 of detection down to 4 copies of viral RNA (Fig 2C). These calibration curves were retrospectively
140 used to calculate the detection limit of our own viral RNA serial dilution (Fig 2B), showing that in
141 these experiments our assays detected between 1 and 3 copies of genomic SARS-CoV-2 RNA.

142

143 **N1E-RP and N2E-RP multiplex assays correctly identify positive patient samples**

144 Next, to further establish assay reproducibility in a diagnostics context, the N1E-RP and N2E-RP
145 assays were performed on an additional 89 patient samples, and results compared to the TaqPath
146 assay. The patient samples contained both SARS-CoV-2 positives and negatives, and were tested
147 blind. Internal controls were included to provide confirmation of successful nucleic acid extraction
148 and absence of PCR inhibitors, with lysis buffer spiked with both MS2 (an RNA bacteriophage that
149 infects *Escherichia coli*) and PhHV (a DNA virus that infects seals), detected by the TaqPath and N1E-
150 RP/N2E-RP assays respectively. In addition, the same three controls were performed for each assay:
151 an extracted viral transport medium control (negative for SARS-CoV-2 and *RPP30*, positive for PhHV),
152 a non-extracted water only control (negative for all targets) and a non-extracted in vitro transcribed
153 RNA positive control (50 copies; positive for SARS-CoV-2, negative for *RPP30* and PhHV).

154 Results for controls were as anticipated (Table S4), with signal absent (undetermined) for SARS-CoV-
155 2 and *RPP30* targets for the negative controls, and Cq values for the SARS-CoV-2 RNA positive
156 control (50 copies) similar to those obtained previously (Fig 2A). The PhHV control gave consistent
157 Cq values for both N1E-RP (32.5 ± 1.1) and N2E-RP assays (33.3 ± 1.2; Table S4, Fig S2A), confirming
158 reliable and reproducible extraction of nucleic acids from patient samples; similar to the MS2 control
159 used in the TaqPath assay (mean Cq value, 25.6 ± 0.9; Table S4, Fig S2A). Out of the 89 samples, the
160 TaqPath assay identified 75 samples as negative, 1 as inconclusive and 13 as positive. Both the N1E-
161 RP and N2E-RP assay detected the same 13 positive samples, and the majority of TaqPath negative
162 samples were similarly negative in our assays (n = 74). For the N1E-RP assay 6 of the negative
163 samples had Cq values between 39.0 and 43.2 for N1 (E gene not detected), suggesting potentially
164 higher sensitivity of the N1 probe in this assay. The sample that was inconclusive with the TaqPath
165 assay (P75) was positive for both N1E-RP and N2E-RP assays, consistent with this being a true
166 positive. In addition, there was one sample (P53) that was negative with TaqPath, but positive for

167 both N1E-RP and N2E-RP assays, albeit with very high Cq values (between 35.7 and 39.2), close to
168 the limit of detection.

169 Altogether, our data (for n = 108 patient samples) establish that the sensitivity of the N1E-RP and
170 N2E-RP assays is similar to, if not higher than, the TaqPath assay (Fig 3).

171

172 **Substantial variability in NTS quality, as measured by human *RPP30*, impacts on assay sensitivity**

173 The range of Cq values for the human *RPP30* control was much greater than that of the PhHV
174 internal control (Table S4, Fig 4A, B and Fig S2). This indicated that there was considerable variability
175 in the amount of cellular material present in different patient samples. The *RPP30* primer/probe set
176 has good amplification efficiency and was able to detect 10 copies of positive control nucleic acids
177 (Fig S3), hence Cq values for this probe represent a good measure of the presence of intact cellular
178 nucleic acids in patient samples. Although *RPP30* was detected in all samples, Cq values ranged from
179 20.1 to 31.7 for the N1E-RP assay and from 20.3 to 32.1 for the N2E-RP assay, which equates to a
180 difference of between 3,100 and 3,600-fold in extracted nucleic acids between the best and worst
181 samples. Although the distribution of positives (Fig 4A, B) shows that samples with high *RPP30* Cq
182 values can still test positive, this is not an adequate measure of the likelihood of false negatives
183 among samples with similarly low levels of human material. A statistically significant linear
184 correlation between Cq values for each of the viral probes (E, N1, and N2) and the Cq values for the
185 *RPP30* sample quality probe ($p < 0.001$; Fig 4C and data not shown) established that samples
186 containing fewer human cells are more likely to have less SARS-CoV-2, decreasing the chance of
187 detection. To visually demonstrate the impact of this, we normalised SARS-CoV-2 Cq values to the
188 sample with the lowest amount of human material detected (reference sample, *RPP30* Cq value
189 31.7/32.1). Due to the linear correlation between *RPP30* and viral Cq values, subtracting the
190 difference in *RPP30* Cq between a particular positive sample and the reference sample from the
191 SARS-CoV-2 Cq gives an indication of what the viral Cq may have been had it contained the same low

192 amount of human material present in the reference sample. This shows that of the 26 positive
193 samples we detected, between 4 and 6 (15-23%) would not have tested positive, with at least one of
194 the viral targets exceeding the detection limit (Cq > 40; Fig 4D and Fig S4A). Theoretically, using this
195 approach, even a strong positive sample (SARS-CoV-2 Cq value of 28.2) of good quality (*RPP30* Cq
196 value of 20.3) may have given a false negative test result (SARS-CoV-2 Cq value of 40) if it had
197 contained the same low amount of human material as the reference sample (*RPP30* Cq value of
198 32.1; viral Cq: 32.1-20.3+28.2=40). Conversely, normalising samples to an optimal quality sample
199 (RPP30 Cq 20.1/20.3) gives an indication of what viral Cq values may have been if all samples had
200 contained a similar (more optimal) amount of material (Fig 4E, Fig S4B). This highlights the possibility
201 that a proportion of apparent SARS-CoV-2 negative samples are in fact false negatives as a result of
202 insufficient material in the swab fluid. Notably, the SARS-CoV-2 Cq values clustered more strongly
203 after normalisation (Fig 4D, E; Fig S4). This reduced variability not only shows that the amount of
204 human material present in NTS samples impacts on assay sensitivity, but also suggests that
205 variability in viral load is not as great as implied by RT-qPCR data without normalisation.

206

207 Discussion

208 Here, we describe a user-friendly protocol for an accurate and affordable SARS-CoV-2 RT-qPCR test.
209 Although we did not detect substantial differences between our two assays, others have reported
210 higher sensitivity of the N1 over the N2 assay [19]. We therefore recommend the use of the N1E-RP
211 assay for primary testing, and the N2E-RP assay could be employed if initial results are inconclusive.
212 We provide detailed materials and methods to enable others to rapidly set up this assay in their own
213 laboratory or to adapt it to locally available equipment and reagents. While we provide extensive
214 validation of the reagents and instruments used to perform these multiplex RT-qPCR assays, our
215 methods allow some flexibility. Probes with different labels as well as alternative Real-Time PCR
216 machines could be used, as long as the different dyes can be detected simultaneously. Also, spike-in

217 controls other than PhHV could be used, such as recombinant DNA or RNA. However, virus would
218 better mimic extraction of SARS-CoV-2 RNA, and other viruses with an RNA genome (e.g. lentivirus,
219 routinely produced in many molecular biology laboratories) would make particularly good controls,
220 not only confirming successful RNA extraction, but also controlling for RNA stability and reverse
221 transcription. As a further development, replacing E gene with M or S gene probes, could provide
222 N2M or N2S assays as fully independent second line tests. Both M and S gene assays have been
223 shown to have high sensitivity [20, 21] and their target regions display low sequence variation (Table
224 S5). Additional improvements to our protocol could include the use of control primers/probe specific
225 to a human RNA transcript (the *RPP30* primers/probe described here detect both RNA and genomic
226 DNA) as this would ensure that samples contain intact RNA [22]. However, it should be stressed that
227 any changes to the protocol may also change the sensitivity of SARS-CoV-2 detection, and new
228 protocols should undergo appropriate validation before use for diagnostic purposes.

229 Our assays have high analytical sensitivity, equivalent to commercial CE-IVD kits. RT-qPCR tests are
230 molecular tests with high intrinsic accuracy, however false positive and false negative results can
231 occur. The use of multiplex assays that detect multiple SARS-CoV-2 targets, such as those reported
232 here, reduces the chance of both. Off-target reactivity is one possible cause of false positives, and
233 although some have reported high false positive rates for the E gene assay [20, 23], this does not
234 match our experience. In two patients, our N1E-RP and N2E-RP assays detected virus, albeit weakly,
235 whereas commercial assays did not. As multiple SARS-CoV-2 targets were positive, these are likely
236 true positive results and not due to off-target reactivity. False positives can also occur due to lab
237 issues such as sample mislabelling, data entry errors, reagent contamination with target nucleic
238 acids or contamination of primary specimens. However high standards of quality control at all stages
239 of testing, and effective mitigation strategies should quickly identify problems. Additionally, sample
240 re-testing with an independent assay and/or patient re-sampling should also be effective measures
241 to counter false positives, particularly in low pre-test probability situations such as mass screening.

242 False negative test results are an important ongoing issue, estimated to be somewhere between 2
243 and 54% [24-26]. Sequence variation at primer/probe binding sites could be one factor resulting in
244 false negatives. However, for the primers and probes used the chance of this is low (>97.6% of
245 97,782 strains have no relevant changes; Table 2, Table S5), and strains with mutations in two
246 independent targets should be very rare. Therefore sequence variation is not expected to be a
247 significant contributing factor to the number of false negatives. In contrast, low sample quality
248 provides a much more likely explanation; and this may be particularly important in case of self-
249 sampling. Systematic inclusion of a human control to provide sample quality metrics, could therefore
250 have utility in reducing the number of false negatives. Testing saliva, as an alternative to NTS
251 sampling, could also be beneficial as a modality that may have less-sample to sample variability [7].

252 Absence of *RPP30* signal (undetected or Cq >40) clearly indicates that absence of viral detection
253 cannot be interpreted as a negative test result and that a repeat test is required (Table S6).
254 However, utilising *RPP30* Cq values when interpreting an apparent SARS-CoV-2 negative sample
255 requires further consideration: what should the *RPP30* Cq limit be for which to order a repeat test?
256 One option would be to simply set an arbitrary cut-off, e.g. one could decide to re-test any samples
257 with *RPP30* Cq >30, or with Cq values above the 95th centile (Cq ~ 31 for our 108 samples). To
258 determine robust cut-off limits, collection of *RPP30* data for a much larger number of patient
259 samples would be desirable. This would allow development of diagnostic algorithms that could
260 incorporate a sample quality score based on the level of *RPP30* detected. Nonetheless, *RPP30* data,
261 even as it stands, are useful for the interpretation of cases for which only one of the SARS-CoV-2
262 targets is (weakly) positive, with samples with high *RPP30* Cq values interpreted with particular
263 caution. In such cases, repeat testing of the same sample (with an independent assay of equal or
264 better sensitivity) would be advisable, and repeat patient specimen collection and testing might also
265 be considered (see Table S6 for guidance). Ultimately, the clinical sensitivity of any diagnostic test is
266 influenced by multiple factors, including sample timing relative to symptom onset, sample type and
267 sample quality. The inclusion of a human control in our assays provides an internal sample quality

268 control, supporting improved interpretation of test results, which could contribute to reducing false
269 negative rates.

270 Taken together we show that sensitive and robust RT-qPCR assays for the detection of SARS-CoV-2
271 are available at a fraction of the cost of comparable commercial assays. The use of these assays
272 could make widespread population testing more feasible.

273 # Materials and Methods

274 **Patient samples**

275 Samples were collected from symptomatic individuals by trained healthcare professionals using
276 combined nose-and-throat swabbing, and processed for diagnostic testing using validated CE-IVD
277 assays. Excess samples were then used to validate the in-house multiplex assays, with specimen
278 anonymization by coding, compliant with Tissue Governance for the South East Scotland Scottish
279 Academic Health Sciences Collaboration Human Annotated BioResource (reference no. SR1452). A
280 variety of swabs and viral transport media (VTM) were used. In each case, swabs were placed in VTM
281 and kept at ambient temperature until processed (within 24 h).

282

283 **Nucleic Acid isolation**

284 Nucleic acids were isolated using the Omega Mag-Bind Viral DNA/RNA 96 Kit (Cat. No. M6246),
285 following the Supplementary Protocol for NP Swabs (April 2020 version). Briefly, 200 µl VTM was
286 taken from patient swab sample inside a Class-2 safety cabinet and mixed with 240 µl TNA Lysis
287 Buffer, 1 µl carrier RNA and extraction controls (MS2, provided as part of the TaqPath COVID-19
288 Combo Kit, and PhHV, provided by the laboratory of Jürgen Haas) in screw capped tubes, for virus
289 inactivation. After incubation at room temperature for at least 15 min, samples were transferred
290 from tubes into 96-well KingFisher Deep well plates (Cat. No. 95040450) containing 280 µl
291 isopropanol and 2 µl Mag-Bind Particles per well, using a Biomek NX^{P} Automated Liquid Handler
292 (Beckman Coulter). Plates were then moved and the isolation completed on a KingFisher Flex robot
293 (Cat. No. 5400610) as instructed by the manufacturer, including washes with 350 µL VHB Buffer and
294 2x 350 µL SPR Buffer, and RNA finally eluted in 50 µl of nuclease-free water in KingFisher 96
295 microplates (Cat. No. 97002540). Also see Supplementary Material, Protocol 2.

296 An in-house version of a magnetic bead-based isolation was tested and shown to perform similarly
297 in preliminary experiments (data not shown). The use of this protocol could further reduce the cost
298 per test, but would require additional validation. For details of this RNA isolation protocol, see
299 Supplementary Material, Protocol 2.

300

301 **Primers and probes**

302 Primers and probes (Table 3) were synthesised and HPLC purified by LGC BioSearch Technologies
303 (Risskov, Denmark), and dissolved in IDTE (10 mM Tris, 0.1 mM EDTA, pH 8.0) to prepare 100 µM
304 stocks. Pre-prepared primer/probe mixes (FAM-labelled) for N1, N2 and *RPP30* were obtained from
305 Integrated DNA Technologies (IDT, USA; Cat. No. 10006713). Since we developed our assay, N1, N2
306 and *RPP30* primers and probes also became available from IDT as 100 µM stocks, but can also be
307 purchased from other reputable oligonucleotide synthesis companies. All nucleic acid stocks and
308 dilutions were prepared in Eppendorf DNA LoBind tubes (Cat. No. 10051232).

309 Primer/probe mixes (50x) were prepared for E gene (20 µM E_Sarbeco_F1, 20 µM E_Sarbeco_R2, 10
310 µM TxRd_E_Sarbeco_P1), RdRp (30 µM RdRp_SARSr-F2, 40 µM RdRp_SARSr-R2, 10 µM
311 FAM_RdRp_SARSr-P2), *RPP30* (25 µM Hs_RPP30-F, 25 µM Hs_RPP30-R, 6.25 µM HEX-Hs_RPP30-P)
312 and PhHV (15 µM PhHV-F, 15 µM PhHV-R, 5 µM Cy5-PhHV-P). The N1 and N2 primers/probes were
313 purchased premixed (~13.3x) from IDT. These individual primer/probe mixes, were then used to
314 prepare a single mix for each of the 4-plex assays: 12.5x for RdE-RP (with equal volumes of each of the
315 relevant mixes), 7.4x for N1E-RP and N2E-RP (with equal volumes of the E, *RPP30* and PhHV mixes,
316 combined with 3.7x volumes of N1 or N2 mix). Mixes were stored at -20°C, with working stocks kept
317 at 4°C.

318 Primers and probes included in the TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific, Cat. No.
319 A47814) detect SARS-CoV-2 ORF1ab, N and S gene; those in the Abbott RealTime SARS-CoV-2 assay

320 (Cat. No. 09N77-090) detect RdRp and N gene. Further details are not available, as this information is
321 proprietary.

322

323 **RT-qPCR**

324 All RT-qPCRs were performed on Applied Biosystems 7500 Fast Real-Time PCR Systems with ABI
325 7500 software v2.3, using MicroAmp Fast Optical 0.1 mL 96-well reaction plates (Cat. No. 4346906)
326 and Optical Adhesive film (Cat. No. 4311971). For our assays we used the Takara One Step
327 PrimeScript III RT-qPCR kit (Cat. No. RR600B). These were compared to the TaqPath COVID-19
328 Combo Kit (Thermo Fisher Scientific, Cat. No. A47814) and the Abbott RealTime SARS-CoV-2 assay
329 (Cat. No. 09N77-090), used as instructed by the manufacturer. The TaqPath assay was performed on
330 the ABI 7500 Fast System and the Abbott assay was performed on the M2000 system. Experiments
331 using the 4-plex assay were performed as described below, with a user-friendly protocol provided in
332 Supplementary Material, Protocol 1.

333 Reaction master mixes were prepared (20 µl per reaction) for each assay, before adding 5 µl of
334 template RNA per reaction, brief centrifugation and starting the PCR program. For the RdE-RP 4-plex
335 assay, per reaction 12.5 µl of One-Step mix, 5.5 µl of nuclease-free water, 2 µl of 12.5x primer/probe
336 mix and 5 µl of template RNA were mixed. For the N1E-RP and N2E-RP 4-plex assays, per reaction
337 12.5 µl of One-Step mix, 4.16 µl of nuclease-free water, 3.34 µl of 7.4x primer/probe mix and 5 µl of
338 template RNA were mixed. For all 4-plex reactions the PCR program was: 5 min at 52°C, 10 s at 95°C,
339 then 45 cycles of 3 s at 95°C and 30 s at 60°C. For detection the FAM, JOE, TEXAS RED and CY5
340 channels were used.

341

342 **Amplification efficiency**

343 Amplification efficiency (E) was determined for all standard curves using the slope of the linear curve
344 fit when plotting Cq values versus the log of input amounts. An E of 100% means that the number of
345 molecules of the target sequence double during each replication cycle. The following formula was
346 used: $E = 100 \times (10^{-1/slope} - 1)$.

347

348 **Positive controls**

349 Positive control RNAs generated by in vitro transcription were provided by Sylvie Behillil (Institut
350 Pasteur, Paris, France) for E gene [9] and by Christine Tait-Burkard (Roslin Institute, Edinburgh, UK)
351 for RdRp [13, 14], N1/N3 and N2 [9]. An equimolar mix of all RNAs was prepared at 2.5×10^8
352 copies/µl, and aliquots stored at -80°C. Dilution series were prepared in nuclease-free water, in
353 Eppendorf DNA LoBind tubes (Cat. No. 10051232), at 2,000, 200, 20, 10, 2 and 0.2 copies/µl.

354 A cultured SARS-CoV-2 control (strain hCoV-19/England/02/2020; GISAID Accession EPI_ISL_407073,
355 [27-29]) was provided by Rory Gunson (NHS Molecular Development in Virology and Microbiology,
356 Glasgow, UK). Except for the reported S15519T mismatch in RdRp-SARSr_R1 [19], this strain has no
357 mutations in target sites for the primers and probes used in our assays [30].

358

359 **QCMD controls**

360 Quality Control for Molecular Diagnostics (Glasgow, UK) provided controls as part of the "QCMD
361 2020 Coronavirus Outbreak Preparedness (CVOP) EQA Pilot Scheme" [31]. RNA extractions were
362 performed using 200 µl of each sample, eluting in 50 µl. After samples were tested blind with our
363 assays, expected results along with sample identities were provided by QCMD. Quantification of
364 control samples was carried out by QCMD prior to distribution within the EQA scheme, using droplet
365 digital PCR (ddPCR) with E-gene primers and probe [13, 14] on the Biorad droplet digital PCR
366 platform. A serial dilution of inactivated SARS-CoV-2 (strain BetaCoV/Munich/ChVir984/2020;

367 GenBank Accession MT270112, [32]) was prepared and each dilution replicate tested 4 times using
368 both RT-qPCR and ddPCR assays. Regression analysis was used to assess the linearity across the
369 dilution series, and the analytical measurement range established for both assays, comparing results
370 of each by Bland-Altman difference plot. Except for the reported S15519T mismatch in RdRp-
371 SARSr_R1 [19], this strain has no mutations in target sites for the primers and probes used in our
372 assays [30]. Concentrations determined by ddPCR in Log10 dPCR copies/ml were used to calculate
373 the number of copies of input RNA.

374

375 **Statistical analysis**

376 To determine whether a linear relationship exists between the observed Cq values for viral probes
377 and the *RPP30* (sample quality) probe, we used Pearson's correlation coefficient and linear
378 regression. Linear regression p-values were calculated using an F-test. Qualitative visual model
379 diagnostics indicated in each case that the statistical assumptions of linear regression models were
380 not violated; in particular the normality and homoscedasticity of residuals. Statistical analysis was
381 performed using R version 4.0.3 [33].

382

383 **Primer/probe mismatch analysis**

384 SARS-CoV-2 (hCoV-19) genome sequences and multiple sequence alignment (MSA) of 131,759
385 strains were downloaded from the GISAID EpiCov^{TM} database [27, 29]. Local alignments were
386 generated between each oligo and the hCoV-19/Wuhan/WIV04/2019 reference strain using
387 biopython's pairwise2 module [34]. Alignment coordinates were then transposed to the
388 corresponding positions in the MSA. For each strain sequence in the MSA, mismatches and gaps
389 were counted; where mixed bases (IUPAC ambiguity codes with the exception of N) were present in
390 either oligo or strain sequence a position was considered to "match" if there was overlap between

391 the mixed bases. If either oligo sequence or strain sequence contained gaps relative to one another
392 a pairwise local alignment was performed between the oligo and the strain sequence corresponding
393 to the oligo position ± 20 flanking nucleotides in order to detect any ungapped matches between
394 strain sequence and oligo.

395 To ensure only high-quality sequences were included in the analysis, genome sequences with >1%
396 Ns or with gaps ≥ 95th percentile were excluded. Sequences with Ns in oligo regions were also
397 excluded, leaving a total of 97,782 sequences. Code used to count mismatches between strains and
398 oligos is provided at https://github.com/david-a-parry/SARS-CoV-2_oligos_vs_strains.

399 ## Acknowledgments

400 We thank Sylvie Behillil (Institut Pasteur, Paris, France), Rory Gunson (NHS Molecular Development
401 in Virology and Microbiology, Glasgow, UK), and Paul Wallace (QCMD, Glasgow, UK) for reagents and
402 information; and Angela Ingram, Derek Mills, Maggie Arbuckle, Joyce Begbie, Heather Coupar, Eilidh
403 Guild, Samantha Griffiths, Garry Jempson, Alain Kemp, Frances Rae, and Thomas Williams for
404 support. CT-B and MO'S were funded by BBSRC Institute Strategic Programme grant funding
405 (BBS/E/D/20002172, BBS/E/D/20002173). This work was supported by a UK Medical Research
406 Council Human Genetics Unit core grant (MRC, U127580972) and by NHS National Services Scotland,
407 as part of a technology development exercise at the NHS-led University of Edinburgh/NHS Lothian
408 COVID-19 testing centre at the Institute of Genetics and Molecular Medicine.

409

410 ## Author contributions

411 MAMR, APJ, conceived the project. MAMR, LT, JCA, ADi, ADa, KT, JGH, NG, designed experiments.
412 MAMR, LT, JCA, HAB, NG, performed RNA extractions and RT-qPCR experiments. ADa, MCS,
413 performed viral inactivation experiments. FJS-L, CU, MA, ETF, TH, EJJ, FLMC, JKR, MW, CD, DL, CM,
414 SJW, SM, LS, MA, DM, provided technical assistance. MAMR, LT, JCA, HAB, DAP, ADa, AO'C, analysed
415 data. MO'S, MLLM, NW, JS, KT, CT-B, JGH, provided reagents. MAMR, DM, KT, CT-B, JGH, IRA, APJ,
416 supervised the work. IPMT, DM, NW, IJ, IRA, APJ, provided administrative organisation. MAMR, APJ,
417 wrote the manuscript. All authors had the opportunity to edit the manuscript and approved the final
418 manuscript.

419

420 ## Supplementary information

421 Supplementary material includes 4 figures, 6 tables, 2 protocols and 1 additional file.

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33. Epub 2020/01/25. doi: 10.1056/NEJMoa2001017. PubMed PMID: 31978945; PubMed Central PMCID: PMCPMC7092803.
2. WHO. Coronavirus disease (COVID-19) Weekly Epidemiological Update 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
3. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533-4. Epub 2020/02/23. doi: 10.1016/S1473-3099(20)30120-1. PubMed PMID: 32087114; PubMed Central PMCID: PMCPMC7159018.
4. Azzi L, Carcano G, Gianfagna F, Grossi P, Gasperina DD, Genoni A, et al. Saliva is a reliable tool to detect SARS-CoV-2. J Infect. 2020;81(1):e45-e50. Epub 2020/04/17. doi: 10.1016/j.jinf.2020.04.005. PubMed PMID: 32298676; PubMed Central PMCID: PMCPMC7194805.
5. Iwasaki S, Fujisawa S, Nakakubo S, Kamada K, Yamashita Y, Fukumoto T, et al. Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva. J Infect. 2020;81(2):e145-e7. Epub 2020/06/07. doi: 10.1016/j.jinf.2020.05.071. PubMed PMID: 32504740; PubMed Central PMCID: PMCPMC7270800 interests.
6. Mohammadi A, Esmaeilzadeh E, Li Y, Bosch RJ, Li JZ. SARS-CoV-2 detection in different respiratory sites: A systematic review and meta-analysis. EBioMedicine. 2020;59:102903. Epub 2020/07/29. doi: 10.1016/j.ebiom.2020.102903. PubMed PMID: 32718896; PubMed Central PMCID: PMCPMC7380223.
7. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P, et al. Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. N Engl J Med. 2020;383(13):1283-6. Epub 2020/08/29. doi: 10.1056/NEJMc2016359. PubMed PMID: 32857487; PubMed Central PMCID: PMCPMC7484747.
8. Brown JR, O'Sullivan D, Pereira RP, Whale AS, Busby E, Huggett J, et al. Comparison of SARS-CoV2 N gene real-time RT-PCR targets and commercially available mastermixes. 2020:2020.04.17.047118. doi: 10.1101/2020.04.17.047118 %J bioRxiv.
9. WHO in-house assays COVID-19 RT-qPCR 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/whoinhouseassays.pdf?sfvrsn=de3a76aa_2.
10. Kim D, Lee JY, Yang JS, Kim JW, Kim VN, Chang H. The Architecture of SARS-CoV-2 Transcriptome. Cell. 2020;181(4):914-21 e10. Epub 2020/04/25. doi: 10.1016/j.cell.2020.04.011. PubMed PMID: 32330414; PubMed Central PMCID: PMCPMC7179501.
11. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe. 2020;27(3):325-8. Epub 2020/02/09. doi: 10.1016/j.chom.2020.02.001. PubMed PMID: 32035028; PubMed Central PMCID: PMCPMC7154514.
12. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-9. Epub 2020/02/06. doi: 10.1038/s41586-020-2008-3. PubMed PMID: 32015508; PubMed Central PMCID: PMCPMC7094943.
13. Corman VM, et al. Diagnostic detection of 2019-nCoV by real-time RT-PCR, protocol v2 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf.
14. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3). Epub 2020/01/30. doi: 10.2807/1560-7917.ES.2020.25.3.2000045. PubMed PMID: 31992387; PubMed Central PMCID: PMCPMC6988269.
15. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology. 2020:200642. Epub 2020/02/27. doi: 10.1148/radiol.2020200642. PubMed PMID: 32101510; PubMed Central PMCID: PMCPMC7233399.

16. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55(4):611-22. Epub 2009/02/28. doi: 10.1373/clinchem.2008.112797. PubMed PMID: 19246619.
17. Niesters HG. Quantitation of viral load using real-time amplification techniques. Methods. 2001;25(4):419-29. Epub 2002/02/16. doi: 10.1006/meth.2001.1264. PubMed PMID: 11846611.
18. Stranska R, Schuurman R, de Vos M, van Loon AM. Routine use of a highly automated and internally controlled real-time PCR assay for the diagnosis of herpes simplex and varicella-zoster virus infections. J Clin Virol. 2004;30(1):39-44. Epub 2004/04/10. doi: 10.1016/j.jcv.2003.08.006. PubMed PMID: 15072752.
19. Vogels CBF, Brito AF, Wyllie AL, Fauver JR, Ott IM, Kalinich CC, et al. Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets. Nat Microbiol. 2020. Epub 2020/07/12. doi: 10.1038/s41564-020-0761-6. PubMed PMID: 32651556.
20. Toptan T, Hoehl S, Westhaus S, Bojkova D, Berger A, Rotter B, et al. Optimized qRT-PCR Approach for the Detection of Intra- and Extra-Cellular SARS-CoV-2 RNAs. Int J Mol Sci. 2020;21(12). Epub 2020/06/25. doi: 10.3390/ijms21124396. PubMed PMID: 32575728; PubMed Central PMCID: PMCPMC7352576.
21. Zhen W, Berry GJ. Development of a New Multiplex Real-Time RT-PCR Assay for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Detection. J Mol Diagn. 2020. Epub 2020/09/23. doi: 10.1016/j.jmoldx.2020.09.004. PubMed PMID: 32961315; PubMed Central PMCID: PMCPMC7501774.
22. Dekker RJ, Ensink WA, van Leeuwen S, Rauwerda H, Breit TM. Overhauling a faulty control in the CDC-recommended SARS-CoV-2 RT-PCR test panel. 2020:2020.06.12.147819. doi: 10.1101/2020.06.12.147819 %J bioRxiv.
23. Konrad R, Eberle U, Dangel A, Treis B, Berger A, Bengs K, et al. Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020. Euro Surveill. 2020;25(9). Epub 2020/03/12. doi: 10.2807/1560-7917.Es.2020.25.9.2000173. PubMed PMID: 32156330; PubMed Central PMCID: PMCPMC7068163.
24. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, Zambrano-Achig P, del Campo R, Ciapponi A, et al. False-negative results of initial RT-PCR assays for COVID-19: A systematic review. 2020:2020.04.16.20066787. doi: 10.1101/2020.04.16.20066787 %J medRxiv.
25. Watson J, Whiting PF, Brush JE. Interpreting a covid-19 test result. BMJ. 2020;369:m1808. Epub 2020/05/14. doi: 10.1136/bmj.m1808. PubMed PMID: 32398230.
26. Woloshin S, Patel N, Kesselheim AS. False Negative Tests for SARS-CoV-2 Infection - Challenges and Implications. N Engl J Med. 2020;383(6):e38. Epub 2020/06/06. doi: 10.1056/NEJMp2015897. PubMed PMID: 32502334.
27. Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID's innovative contribution to global health. Glob Chall. 2017;1(1):33-46. Epub 2017/01/10. doi: 10.1002/gch2.1018. PubMed PMID: 31565258; PubMed Central PMCID: PMCPMC6607375.
28. Pybus OR, A; Du Plessis, L; Zarebski, AE; Kraemer, MUG, Raghwani, J; Gutiérrez, B; Hill, V; McCrone, J, Colquhoun, R; Jackson, B; O'Toole, Á; Ashworth J on behalf of the COG-UK consortium. Preliminary analysis of SARS-CoV-2 importation & establishment of UK transmission lineages. virologicalorg. 2020.
29. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data - from vision to reality. Euro Surveill. 2017;22(13). Epub 2017/04/07. doi: 10.2807/1560-7917.ES.2017.22.13.30494. PubMed PMID: 28382917; PubMed Central PMCID: PMCPMC5388101.
30. Singer JG, R.; Cotten, M.; Robertson, D. CoV-GLUE: A Web Application for Tracking SARS-CoV-2 Genomic Variation. Preprints. 2020. doi: 10.20944/preprints202006.0225.v1.
31. Matheeussen V, Corman VM, Donoso Mantke O, McCulloch E, Lammens C, Goossens H, et al. International external quality assessment for SARS-CoV-2 molecular detection and survey on clinical laboratory preparedness during the COVID-19 pandemic, April/May 2020. Euro Surveill.

522 2020;25(27). Epub 2020/07/17. doi: 10.2807/1560-7917.ES.2020.25.27.2001223. PubMed PMID:
523 32672149; PubMed Central PMCID: PMCPMC7364759.
524 32. Bohmer MM, Buchholz U, Corman VM, Hoch M, Katz K, Marosevic DV, et al. Investigation of
525 a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case
526 series. Lancet Infect Dis. 2020;20(8):920-8. Epub 2020/05/19. doi: 10.1016/S1473-3099(20)30314-5.
527 PubMed PMID: 32422201; PubMed Central PMCID: PMCPMC7228725.
528 33. R Core Team. R: A language and environment for statistical computing. R Foundation for
529 Statistical Computing, Vienna, Austria. 2020. Available from: https://www.R-project.org/.
530 34. Cock PJ, Antao T, Chang JT, Chapman BA, Cox CJ, Dalke A, et al. Biopython: freely available
531 Python tools for computational molecular biology and bioinformatics. Bioinformatics.
532 2009;25(11):1422-3. Epub 2009/03/24. doi: 10.1093/bioinformatics/btp163. PubMed PMID:
533 19304878; PubMed Central PMCID: PMCPMC2682512.

Table 1 | The multiplex assay detecting RdRp and E gene (RdE-RP) is not sufficiently sensitive; assays detecting N and E gene (N1E-RP, N2E-RP) are

	RdE-RP		N1E-RP		N2E-RP		All assays	TaqPath assay			Abbott	Conclusion				
Patient	**E**	**RdRp**	**E**	**N1**	**E**	**N2**	**RPP30**	**N**	**S**	**ORF1ab**	**Cq***	**RdE -RP**	**N1E-RP**	**N2E-RP**	**Taq Path**	**Abbott**
P1	UD	UD	UD	UD	UD	UD	28.2 ± 0.56	UD	UD	UD	UD	N	N	N	N	N
P2	UD	UD	UD	UD	UD	UD	31.8 ± 0.58	UD	UD	UD	UD	N	N	N	N	N
P3	UD	UD	UD	UD	UD	UD	29.3 ± 0.54	UD	UD	UD	UD	N	N	N	N	N
P4	UD	UD	UD	UD	UD	UD	27.8 ± 0.51	UD	UD	UD	UD	N	N	N	N	N
P5	18.72	24.17	18.19	19.33	17.50	18.16	22.7 ± 1.37	20.09	20.73	20.03	18.26	P	P	P	P	P
P6	20.58	25.39	19.90	21.55	20.27	20.28	24.9 ± 1.65	22.80	22.78	22.04	21.39	P	P	P	P	P
P7	24.23	28.65	23.41	25.09	22.85	23.97	27.1 ± 0.79	25.94	26.27	25.64	23.70	P	P	P	P	P
P8	25.74	32.33	25.26	26.09	24.56	24.92	27.6 ± 0.49	27.00	27.90	27.19	25.78	P	P	P	P	P
P9	UD	UD	UD	UD	UD	UD	28.2 ± 0.29	UD	UD	UD	UD	N	N	N	N	N
P10	UD	UD	UD	UD	UD	UD	27.9 ± 0.48	UD	UD	UD	UD	N	N	N	N	N
P11	UD	UD	35.33	37.98	33.95	UD	30.6 ± 0.49	UD	UD	39.42	UD	N	P	Inc	Inc	N
P12	UD	UD	UD	UD	34.81	38.03	27.5 ± 0.33	UD	UD	UD	UD	N	N	P	N	N
P13	20.26	24.85	19.54	20.76	18.94	19.73	24.1 ± 1.64	21.35	22.41	21.85	19.84	P	P	P	P	P
P14	UD	UD	UD	UD	UD	UD	27.9 ± 0.49	UD	UD	UD	UD	N	N	N	N	N
P15	25.50	31.64	24.94	27.06	24.37	25.43	25.9 ± 0.38	27.50	27.30	26.73	25.27	P	P	P	P	P
P16	UD	UD	UD	UD	UD	UD	27.9 ± 0.36	UD	UD	UD	UD	N	N	N	N	N
P17	17.44	26.97	17.23	16.08	16.85	16.93	21.9 ± 1.67	16.06	18.46	17.02	14.16	P	P	P	P	P
P18	29.77	UD	29.17	31.10	29.20	30.28	29.7 ± 0.43	31.54	31.30	30.71	30.32	Inc	P	P	P	P
P19	31.76	UD	31.13	34.03	30.21	32.40	27.4 ± 0.63	33.87	35.22	33.71	32.49	Inc	P	P	P	P

* The output for the Abbott test, which detects RdRp and N gene, is given in a single CN value, which is approximately equivalent to Cq minus 10 (so Cq = CN+10)
UD, undetermined; P, positive; N, negative; Inc, inconclusive

Table 2 | Percentage of known SARS-CoV-2 genomic sequences with mutations in primer/probe binding sites for E gene, N1 and N2 assays

Assay	Primer/probe	Percentage of strains with any mismatch/deletion*		Percentage of strains with mismatch in 5 most 3' nt*	
		Per primer/probe	Per assay**	Per primer	Per assay***
E gene	E_Sarbeco-F1	0.10%	0.26%	0.006%	0.007%
	E_Sarbeco-P1	0.12%		(0.008%)	
	E_Sarbeco-R2	0.04%		0.001%	
N1	2019-nCoV_N1-F	0.29%	2.39%	0.034%	0.157%
	2019-nCoV_N1-P	1.79%		(0.057%)	
	2019-nCoV_N1-R	0.33%		0.124%	
N2	2019-nCoV_N2-F	0.35%	1.82%	0.153%	0.169%
	2019-nCoV_N2-P	0.33%		(0.008%)	
	2019-nCoV_N2-R	1.19%		0.015%	

High quality genome sequences analysed only (n=97,782).

* 0-0.003% of genomes have deletions in primer/probe binding regions, so majority are mismatches. Presence of these changes does not necessarily impact on primer/probe performance. Mutations at the 3’ ends for the primer regions (here defined as the final 5 nt) are more likely to affect assay sensitivity.

** Mismatches/deletions in the primer/probe set used in single target assay

*** Mismatches in the forward and reverse primers only. For probes values are given between brackets for reference (in the “per primer” column).

Table 3 | Primer/Probe details for 4-plex assays

Target	Oligonucleotide ID	Sequence (5'-3')	Concentration (nM)	PCR Product Size	Reference
SARS-CoV-2 E gene	E_Sarbeco_F1	ACAGGTACGTTAATAGTTAATAGCGT	400	113 bp	[7, 8]
	E_Sarbeco_R2	ATATTGCAGCAGTACGCACACA	400		
	TxRd_E_Sarbeco_P1*	CFR-610-ACACTAGCCATCCTTACTGCGCTTCG-BHQ2	200		
SARS-CoV-2 RdRp	RdRp_SARSr-F2	GTGARATGGTCATGTGTGGCGG	600	100 bp	[7, 8]
	RdRp-SARSr-R1	CARATGTTAAASACACTATTAGCATA	800		
	FAM_RdRp_SARSr-P2	FAM-CAGGTGGAACCTCATCAGGAGATGC-BHQ1	200		
SARS-CoV-2 N gene	2019-nCoV_N1-F	GACCCCAAAATCAGCGAAAT	500	72 bp	[4]
	2019-nCoV_N1-R	TCTGGTTACTGCCAGTTGAATCTG	500		
	2019-nCoV_N1-P	FAM-ACCCCGCATTACGTTTGGTGGACC-BHQ1	125		
SARS-CoV-2 N gene	2019-nCoV_N2-F	TTACAAACATTGGCCGCAAA	500	67 bp	[4]
	2019-nCoV_N2-R	GCGCGACATTCCGAAGAA	500		
	2019-nCoV_N2-P	FAM-ACAATTTGCCCCCAGCGCTTCAG-BHQ1	125		
Human *RPP30*	Hs_RPP30-F	AGATTTGGACCTGCGAGCG	500	65 bp	[4]
	Hs_RPP30-R	GAGCGGCTGTCTCCACAAGT	500		
	HEX-Hs_RPP30-P	HEX–TTCTGACCTGAAGGCTCTGCGCG–BHQ1	125		
PhHV-1 Glycoprotein B	PhHV-F	GGGCGAATCACAGATTGAATC	300	89 bp	[11]
	PhHV-R	GCGGTTCCAAACGTACCA	300		
	Cy5-PhHV-P**	Quasar-670-TTTTTATGTGTCCGCCACCATCTGGATC-BHQ2	100		

* Probe named TxRd for simplicity, CAL Flour Red (CFR-610) has virtually identical properties to TexRed

** Probe named Cy5 for simplicity. Quasar 670 has virtually identical properties to Cy5

RdRp_SARSr-F2 and RdRp-SARSr-R1, IUPAC codes: S = G or C; R = A or G



Figure 1 | Primers and probes used in our multiplex qRT-PCR assays detect SARS-CoV-2 RNA.

A: Location of qRT-PCR amplicons on the SARS-CoV-2 genome. Open reading frames (ORFs) and qRT-PCR target sites (orange, blue) in RdRp, E and N gene indicated. After a -1 ribosomal frameshift (arrow head) on ORF1ab of the genomic RNA, the pp1ab polypeptide is formed and RdRp/nsp12 released by proteolytic cleavage (dotted lines). Genes 3' of ORF1ab on the positive-sense genome (including E and N) are transcribed (from negative-sense RNA) as subgenomic RNAs and include a short leader sequence (L, black box) at their 5' ends [10].

B: qRT-PCR primers (grey) and probes (colour) used in this study. PCR product sizes are indicated between brackets. Yellow and red lines in RdRp primers indicate degenerate nucleotides and a mismatch respectively (as present in the original design [14]). To detect RdRp we used the RdRp_SARSr-P2 probe, which detects 2019-nCoV/SARS-CoV-2 and not SARS-CoV. The N1 and N2 assays are specific to SARS-CoV-2 , whereas the E gene assay also detects SARS-CoV [9,13,14].

C: Probes used in the RdE-RP, N1E-RP and N2E-RP 4-plex assays detect 2 SARS-CoV-2 targets and 2 controls.

D: Using our 4-plex assays, E, N1 and N2 give Cq values (mean ± SD, n = 2 experiments) comparable those for ORF1ab, S and N from the TaqPath assay (mean of technical triplicates, n = 1 experiment) when detecting cultured SARS-CoV-2.



Figure 2 | The N1E-RP and N2E-RP 4-plex assays detect between 1 and 10 copies of SARS-CoV-2 RNA. N1E-RP and N2E-RP RT-qPCR assays were performed with the following controls

A: 1 to 10,000 copies of SARS-CoV-2 control RNA (IVT, in vitro transcribed);

B: Serial dilution of RNA isolated from cultured SARS-CoV-2 (hCoV-19/England/02/2020). Mean ± SD for technical triplicates shown for A and B. Also, see Table S1 and S2.

C: RNA isolated from QCMD viral controls (BetaCoV/Munich/ChVir984/2020). These controls contained different amounts of SARS-CoV-2 virus at known copy number (see Materials and Methods for details; also see Table S3). R^2 values for logarithmic trend line fitting; E, amplifcation efficiency (see Materials and Methods).



Figure 3 | The N1E-RP and N2E-RP 4-plex assays perform similarly to the TaqPath assay, correctly identifying positive and negative patient samples.

A: The Taqpath, N1E-RP and N2E-RP assays each identified a similar numbers of positives and negatives among 108 patient samples. Inconclusive: only one of the SARS-CoV-2 targets was detected.

B: Cq values for each of the SARS-CoV-2 targets in the TaqPath (N, Orf1ab, S), N1E-RP (N1, E) and N2E-RP (N2, E) were comparable (for n=24-26 positive patients). Also, see Table 1 and S4.



Figure 4|The *RPP30* control indicates substantial variability in sample quantity/quality, impacting on assay sensitivity.

A, B: *RPP30* Cq values for 108 patient samples ranked from low to high (based on N1E-RP ranks) for N1E-RP and N2E-RP assays. SARS-CoV-2 positives, marked in red, are detected for samples with low as well as high RPP30 Cq values.

C: *RPP30* and SARS-CoV-2 Cq values are highly correlated, demonstrating that samples with fewer human cells have lower levels of SARS-CoV-2, supporting the validity of *RPP30* Cq as a measure of sample quality. r, Pearson's correlation coefficient; p-value calculated by F-test.

D, E: Normalisation to *RPP30* levels increases clustering of viral Cq values. Reduced variability in apparent SARS-CoV-2 levels when normalising to the worst (highest *RPP30* Cq; **D**) as well as the best (lowest *RPP30* Cq; **E**) sample. Plots in panel **D** demonstrate the impact of sample quality on assay sensitivity, with 4-6 positives (15-23%) below the detection limit (above the red line, viral Cq > 40) for a worst quality sample scenario.

Supplementary material to:

A sensitive and affordable multiplex RT-qPCR assay for SARS-CoV-2 detection

Martin A.M. Reijns[1,*], Louise Thompson[2], Juan Carlos Acosta[3], Holly A. Black[2,4], Francisco J. Sanchez-Luque[1,5], Austin Diamond[2], David A. Parry[1], Alison Daniels[6], Marie O'Shea[7], Carolina Uggenti[4], Maria C. Sanchez[6], Alan O'Callaghan[1], Michelle L.L. McNab[6], Martyna Adamowicz[4], Elias T. Friman[1], Toby Hurd[1], Edward J. Jarman[1], Frederic Li Mow Chee[3], Jacqueline K. Rainger[1], Marion Walker[3], Camilla Drake[1], Dasa Longman[1], Christine Mordstein[1,8], Sophie J. Warlow[4], Stewart McKay[1], Louise Slater[2], Morad Ansari[2], Ian P.M. Tomlinson[3], David Moore[2], Nadine Wilkinson[9], Jill Shepherd[9], Kate Templeton[9], Ingolfur Johannessen[9], Christine Tait-Burkard[7], Jürgen G. Haas[6], Nick Gilbert[1], Ian R. Adams[1], Andrew P. Jackson[1]

1. MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh, Edinburgh, UK

2. NHS Lothian, The South East of Scotland Clinical Genetic Service, Western General Hospital, Edinburgh, UK

3. Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh, Edinburgh, UK

4. Centre for Genomic & Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh, Edinburgh, UK

5. Centre Pfizer-University of Granada-Andalusian Government for Genomics and Oncological Research (Genyo), Granada, Spain

6. Division of Infection Medicine, Edinburgh Medical School, The University of Edinburgh, Edinburgh, UK

7. The Roslin Institute and Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Edinburgh, UK

8. The Milner Centre for Evolution, Department of Biology and Biochemistry, University of Bath, Bath, UK

9. NHS Lothian, Medical Microbiology and Virology Service, Royal Infirmary of Edinburgh, Edinburgh UK

* Correspondence to MAMR, martin.reijns@igmm.ed.ac.uk

Supplementary material: 4 figures, 6 tables, 2 protocols and 1 additional file



Figure S1 | RNA extraction has no substantial impact on the sensitivity of the N1E-RP and N2E-RP 4-plex assays.

N1E-RP and N2E-RP RT-qPCR assays were performed on

A: 1 to 10,000 copies of SARS-CoV-2 control RNA (IVT, in vitro transcribed) before (as Fig 2A) and after nucleic acid extraction;

B: a serial dilution of RNA isolated from cultured SARS-CoV-2, before (as Fig 2B) and after re-extraction. Mean ± SD for technical triplicates; R^2 values for logarithmic trend line fitting and amplification efficiencies (E) for samples after (re)extraction. Also, see Table S1 and S2.



Figure S2 | High reproducibility for extraction controls, but high variability for the human *RPP30* control in NTS samples.

A, B: Cq values for internal controls, MS2 for TaqPath and PhHV for N1E-RP and N2E-RP assays (A), and *RPP30* controls (B).

C: Cq values for PhHV and *RPP30* controls for N1E-RP and N2E-RP assays, ranked by *RPP30* values from the N1E-RP assay, confirm that variability does not substantially correlate with extraction efficiency.



Figure S3 | The human *RPP30* control probe can detect 10 copies of control DNA.

A: Cq values for *RPP30* on a serial dilution of positive control plasmid DNA (100,000 down to 10 copies were tested).

B: Cq values for *RPP30* on nucleic acids (NA) isolated from human cultured cells (1 = undiluted) and NA isolated from a serial dilution of the same cell suspension show a strong linear correlation and 92% primer efficiency. Negative control samples did not show any amplification. Data points and error bars, mean ± SD (n = 2 technical replicates). R^2 values for logarithmic trend line fitting; E, amplification efficiency.



Figure S4|Increased chance of false negatives for low quality NTS samples, with high *RPP30* Cq values.

A, B: Comparison of actual (Act) and *RPP30*-normalised (Norm) Cq values for SARS-CoV-2 targets shows that values cluster more strongly after normalisation, both when normalising to the worst (highest *RPP30* Cq; **A**) and best (lowest *RPP30* Cq; **B**). Increased clustering (i.e. reduced variability) demonstrates the impact of the correlation between quantity of human and viral nucleic acids in NTS samples (Fig 4C). This shows 1) that sample quality substantially impacts on assay sensitivity and 2) that variability in viral loads is smaller than non-normalised data suggest. Plots in **A** demonstrate that 4-6 positives (15-23%) would likely have been below the detection limit (above the red line, viral Cq > 40) in a worst quality sample scenario.

Table S1 | N1E-RP and N2E-RP assay Cq values for SARS-CoV-2 RNA controls (1 to 10,000 copies) pre- and post-extraction (values used for Fig 2A and Fig S1A)

# copies	10,000	1,000	100	50	10	1
N1, N1E-RP assay pre-extraction						
Rep 1	22.83	26.49	30.30	31.42	33.49	35.87
Rep 2	23.36	26.62	30.50	31.05	34.43	Undetermined
Rep 3	23.30	26.77	29.32	32.38	34.94	Undetermined
Mean	23.17	26.62	30.04	31.62	34.29	35.87
E gene, N1E-RP pre-extraction						
Rep 1	24.26	27.98	31.37	33.60	36.26	Undetermined
Rep 2	24.74	27.73	32.73	35.22	Undetermined	Undetermined
Rep 3	24.43	27.90	31.34	32.36	Undetermined	Undetermined
Mean	24.48	27.87	31.81	33.73	36.26	Undetermined
N2, N2E-RP assay pre-extraction						
Rep 1	26.63	30.49	33.99	34.63	37.34	38.72
Rep 2	26.88	29.99	34.01	35.06	Undetermined	Undetermined
Rep 3	26.70	30.58	33.79	37.34	36.99	Undetermined
Mean	26.74	30.35	33.93	34.47	37.16	38.72
E gene, N2E-RP assay pre-extraction						
Rep 1	25.50	28.71	32.84	33.37	35.25	Undetermined
Rep 2	25.70	28.71	33.05	33.24	35.93	36.64
Rep 3	25.50	29.56	32.29	33.85	35.05	Undetermined
Mean	25.57	28.99	32.73	33.49	35.41	36.64
N1, N1E-RP assay post-extraction						
Rep 1	25.64	29.02	33.14	33.59	35.09	Undetermined
Rep 2	25.14	28.80	33.41	33.58	35.37	36.14
Rep 3	25.50	29.01	33.22	33.87	37.62	37.04
Mean	25.43	28.94	33.25	33.68	36.03	36.59
E gene, N1E-RP assay post-extraction						
Rep 1	25.99	29.24	33.26	35.01	35.59	Undetermined
Rep 2	25.39	28.88	34.04	33.87	33.64	Undetermined
Rep 3	25.61	29.22	32.47	33.81	Undetermined	Undetermined
Mean	25.66	29.11	33.26	34.23	34.61	Undetermined
N2, N2E-RP assay post-extraction						
Rep 1	28.69	32.39	36.86	36.01	38.35	Undetermined
Rep 2	28.33	31.69	35.75	35.57	38.17	Undetermined
Rep 3	28.79	32.56	35.40	36.21	Undetermined	Undetermined
Mean	28.60	32.21	36.01	35.93	38.26	Undetermined
E gene, N2E-RP assay post-extraction						
Rep 1	26.72	29.89	33.85	33.40	Undetermined	Undetermined
Rep 2	26.45	30.01	33.38	34.53	35.87	Undetermined
Rep 3	26.96	30.30	33.79	34.56	36.10	36.40
Mean	26.71	30.07	33.67	34.16	35.98	36.40

Table S2 | N1E-RP and N2E-RP assay Cq values for cultured SARS-CoV-2 dilution series (before and after re-extraction; values used for Fig 2B and Fig S1B)

	neat	10^{-1}	10^{-2}	10^{-3}	10^{-4}	10^{-5}	10^{-6}
N1, N1E-RP assay							
1	22.53	26.46	29.42	32.21	37.19	UD	UD
2	22.83	26.03	29.87	32.79	UD	UD	UD
3	22.40	25.96	29.35	33.48	37.16	UD	UD
Mean	22.59	26.15	29.55	32.83	37.18	UD	UD
E gene, N1E-RP assay							
1	21.31	24.77	27.97	31.35	34.22	UD	UD
2	21.38	24.38	28.03	31.50	35.27	UD	UD
3	21.35	24.41	27.84	31.55	35.63	UD	UD
Mean	21.35	24.52	27.94	31.46	35.04	UD	UD
N2, N2E-RP assay							
1	23.08	26.76	29.95	33.56	37.21	38.06	UD
2	23.36	26.64	29.79	34.81	36.50	38.29	UD
3	23.32	26.46	30.14	33.49	36.44	UD	UD
Mean	23.25	26.62	29.96	33.95	36.72	38.17	UD
E gene, N2E-RP assay							
1	22.00	25.48	28.78	32.41	36.34	UD	UD
2	22.22	25.42	28.57	32.59	UD	40.63	UD
3	22.15	25.31	28.87	32.31	39.68	UD	UD
Mean	22.12	25.40	28.74	32.44	38.01	40.63	UD
	0.5	**10^{-1}**	**10^{-2}**	**10^{-3}**	**10^{-4}**	**10^{-5}**	**10^{-6}**
N1, N1E-RP assay after re-extraction							
1	24.95	27.48	30.79	34.27	UD	UD	UD
2	24.93	27.54	31.08	34.77	37.44	UD	UD
3	25.04	27.12	30.69	34.26	UD	UD	UD
Mean	24.97	27.38	30.85	34.44	37.44	UD	UD
E gene, N1E-RP assay after re-extraction							
1	23.85	26.56	29.63	33.49	UD	UD	UD
2	23.86	26.53	29.85	33.30	UD	UD	UD
3	24.18	26.59	29.59	32.77	35.54	UD	UD
Mean	23.96	26.56	29.69	33.19	35.54	UD	UD
N2, N2E-RP assay after re-extraction							
1	25.90	28.27	31.84	35.46	37.68	UD	UD
2	25.76	28.36	31.78	34.97	UD	UD	UD
3	25.53	28.27	31.13	34.36	UD	UD	UD
Mean	25.73	28.30	31.58	34.93	37.68	UD	UD
E gene, N2E-RP assay after re-extraction							
1	24.86	27.37	30.73	33.22	UD	UD	UD
2	25.00	27.55	30.81	34.54	UD	UD	UD
3	23.65	27.62	31.25	34.19	35.96	UD	UD
Mean	24.51	27.51	30.93	33.99	35.96	UD	UD

Table S3 | N1E-RP, N2E-RP and TaqPath assays all correctly identify COVID-19/SARS-CoV-2 positive QCMD quality control samples

			N1E-RP assay			N2E-RP assay			TaqPath assay			Conclusion		
QCMD Sample	**Content***	**Log10 dPCR Copies/ml****	**N1**	**E**	**PhHV**	**N2**	**E**	**PhHV**	**N**	**ORF1ab**	**S**	**N1E-RP**	**N2E-RP**	**Taq Path**
CVOP20S2-01	SARS-CoV-2	4.30	29.72	28.98	32.22	29.58	29.14	32.98	28.06	28.21	28.15	P	P	P
CVOP20S2-02	Coronavirus – NL63	4.64	UD	UD	33.54	UD	UD	32.79	UD	UD	UD	N	N	N
CVOP20S2-03	SARS-CoV-2	3.30	32.26	31.62	32.66	32.70	31.8	32.52	30.24	29.22	30.02	P	P	P
CVOP20S2-04	Coronavirus – OC43	4.03	UD	UD	32.64	UD	UD	33.01	UD	UD	UD	N	N	N
CVOP20S2-05	Transport medium	-	UD	UD	32.54	UD	UD	32.45	UD	UD	UD	N	N	N
CVOP20S2-06	SARS-CoV-2	4.30	29.77	28.94	32.90	29.56	28.82	32.67	27.96	27.79	27.63	P	P	P
CVOP20S2-07	SARS-CoV-2	5.30	26.18	25.42	31.64	26.20	25.44	31.93	24.63	24.52	24.65	P	P	P
CVOP20S2-08	SARS-CoV-2	2.30	35.69	34.55	33.02	35.66	35.88	32.74	35.89	36.62	36.14	P	P	P

UD, undetermined; P, positive; N, negative

* {Matheeussen, 2020 #17} "SARS-CoV-2 strain BetaCoV/Munich/ChVir984/2020 provided by the Charité-Universitätsmedizin Berlin Institute of Virology, Berlin, Germany; human coronaviruses HCoV-NL63 and HCoV-OC43 cultivated by the University Medical Center Groningen, Groningen, the Netherlands, and sample specifications selected based on past performance data from regular provided coronavirus EQA schemes; negative control sample contained transport medium only (which was used as sample matrix for the EQA samples)."

** Values obtained using ddPCR assay (see Materials and Methods for details). {Matheeussen, 2020 #17}: "Samples CVOP20S-07, -01, -03 and - 08 are in a calibrated dilution series. CVOP20S-06 is a duplicate sample of CVOP20S-01. The values provided are for reference only."

Table S4 | The N1E-RP and N2E-RP COVID-19 4-plex assays perform as well as the TaqPath CE-IVD assay

	N1E-RP assay				N2E-RP assay				TaqPath assay				Conclusion		
Patient	**N1**	**E**	**RPP30**	**PhHV**	**N2**	**E**	**RPP30**	**PhHV**	**N**	**ORF1ab**	**S**	**MS2**	**N1E-RP**	**N2E-RP**	**TaqPath**
P20	UD	UD	25.56	30.74	UD	UD	25.25	31.41	UD	UD	UD	24.31	N	N	N
P21	UD	UD	29.53	34.27	UD	UD	29.76	34.64	UD	UD	UD	26.50	N	N	N
P22	UD	UD	24.59	33.10	UD	UD	24.47	34.14	UD	UD	UD	25.01	N	N	N
P23	UD	UD	30.71	33.47	UD	UD	30.53	33.93	UD	UD	UD	25.90	N	N	N
P24	UD	UD	30.67	33.89	UD	UD	30.57	34.87	UD	UD	UD	26.04	N	N	N
P25	UD	UD	26.81	32.22	UD	UD	26.86	32.71	UD	UD	UD	24.34	N	N	N
P26	UD	UD	26.52	32.60	UD	UD	26.60	33.39	UD	UD	UD	24.22	N	N	N
P27	UD	UD	24.72	32.38	UD	UD	24.83	33.63	UD	UD	UD	25.62	N	N	N
P28	UD	UD	29.83	34.63	UD	UD	29.98	37.73	UD	UD	UD	25.68	N	N	N
P29	UD	UD	25.23	32.30	UD	UD	25.55	32.94	UD	UD	UD	24.59	N	N	N
P30	39.97	UD	26.45	32.73	UD	UD	26.92	33.71	UD	UD	UD	25.62	N	N	N
P31	UD	UD	29.77	33.12	UD	UD	30.10	33.58	UD	UD	UD	25.23	N	N	N
P32	UD	UD	26.34	32.17	UD	UD	26.36	32.39	UD	UD	UD	24.51	N	N	N
P33	UD	UD	24.60	32.81	UD	UD	24.63	33.31	UD	UD	UD	25.25	N	N	N
P34	UD	UD	31.59	34.52	UD	UD	31.11	34.22	UD	UD	UD	25.43	N	N	N
P35	UD	UD	23.00	33.15	UD	UD	22.77	33.35	UD	UD	UD	25.97	N	N	N
P36	UD	UD	25.61	30.87	UD	UD	26.31	32.66	UD	UD	UD	24.95	N	N	N
P37	UD	UD	29.57	34.96	UD	UD	29.28	35.14	UD	UD	UD	25.78	N	N	N
P38	UD	UD	31.26	34.22	UD	UD	31.14	34.67	UD	UD	UD	26.81	N	N	N
P39	UD	UD	21.62	31.94	UD	UD	21.50	32.33	UD	UD	UD	24.79	N	N	N
P40	UD	UD	30.16	33.34	UD	UD	29.42	33.91	UD	UD	UD	25.82	N	N	N
P41	UD	UD	22.61	32.60	UD	UD	22.49	33.39	UD	UD	UD	25.45	N	N	N
P42	UD	UD	21.32	31.32	UD	UD	21.16	32.45	UD	UD	UD	25.23	N	N	N
P43	UD	UD	27.02	32.57	UD	UD	26.31	32.17	UD	UD	UD	25.01	N	N	N

	N1E-RP assay				N2E-RP assay				TaqPath assay				Conclusion		
Patient	**N1**	**E**	**RPP30**	**PhHV**	**N2**	**E**	**RPP30**	**PhHV**	**N**	**ORF1ab**	**S**	**MS2**	**N1E-RP**	**N2E-RP**	**TaqPath**
P44	34.26	31.95	24.16	31.99	33.42	32.56	23.96	32.50	32.77	34.76	33.12	25.17	P	P	P
P45	39.35	UD	30.63	33.82	UD	UD	30.75	35.61	UD	UD	UD	27.19	N	N	N
P46	UD	UD	21.65	31.33	UD	UD	21.68	32.11	UD	UD	UD	24.49	N	N	N
P47	UD	UD	24.73	33.07	UD	UD	24.46	33.90	UD	UD	UD	25.31	N	N	N
P48	UD	UD	24.83	32.74	UD	UD	24.55	33.01	UD	UD	UD	25.82	N	N	N
P49	UD	UD	29.62	33.85	UD	UD	29.32	34.36	UD	UD	UD	26.10	N	N	N
P50	UD	UD	24.81	32.67	UD	UD	24.68	33.23	UD	UD	UD	26.37	N	N	N
P51	UD	UD	30.65	34.44	UD	UD	30.64	37.60	UD	UD	UD	26.99	N	N	N
P52	25.95	24.70	27.20	31.59	25.63	25.35	26.66	32.75	24.55	25.08	25.14	25.97	P	P	P
P53	36.96	37.19	25.79	31.76	36.93	37.77	25.43	32.55	UD	UD	UD	25.63	P	P	N
P54	UD	UD	25.89	32.51	UD	UD	25.75	33.36	UD	UD	UD	25.25	N	N	N
P55	UD	UD	23.41	31.87	UD	UD	23.54	32.70	UD	UD	UD	25.31	N	N	N
P56	UD	UD	28.33	32.86	UD	UD	28.41	33.26	UD	UD	UD	25.66	N	N	N
P57	UD	UD	28.34	32.90	UD	UD	28.40	33.24	UD	UD	UD	26.14	N	N	N
P58	33.38	32.39	30.65	33.38	34.07	33.65	30.10	34.12	33.29	37.49	34.89	26.82	P	P	P
P59	39.03	UD	28.94	32.99	UD	UD	28.64	33.57	UD	UD	UD	25.77	N	N	N
P60	39.53	UD	27.94	31.77	UD	UD	27.67	32.46	UD	UD	UD	25.11	N	N	N
P61	UD	UD	26.81	31.93	UD	UD	26.65	32.29	UD	UD	UD	24.90	N	N	N
P62	UD	UD	32.13	36.32	UD	UD	31.71	36.92	UD	UD	UD	27.27	N	N	N
P63	UD	UD	28.42	32.91	UD	UD	27.90	33.90	UD	UD	UD	25.95	N	N	N
P64	UD	UD	31.67	34.94	UD	UD	31.54	35.91	UD	UD	UD	27.53	N	N	N
P65	UD	UD	22.81	32.49	UD	UD	22.49	33.30	UD	UD	UD	25.98	N	N	N
P66	29.86	29.45	22.54	31.03	30.72	30.51	22.53	31.77	29.45	30.68	30.76	24.86	P	P	P
P67	32.66	31.37	24.95	31.89	32.65	32.39	25.25	32.77	32.25	34.90	33.81	25.78	P	P	P
P68	UD	UD	24.51	32.57	UD	UD	24.28	33.37	UD	UD	UD	25.67	N	N	N
P69	UD	UD	26.49	33.05	UD	UD	26.57	34.02	UD	UD	UD	25.48	N	N	N

	N1E-RP assay				N2E-RP assay				TaqPath assay				Conclusion		
Patient	**N1**	**E**	**RPP30**	**PhHV**	**N2**	**E**	**RPP30**	**PhHV**	**N**	**ORF1ab**	**S**	**MS2**	**N1E-RP**	**N2E-RP**	**TaqPath**
P70	UD	UD	24.67	31.73	UD	UD	24.43	32.22	UD	UD	UD	24.40	N	N	N
P71	40.23	UD	20.35	30.96	UD	UD	20.32	31.66	UD	UD	UD	24.65	N	N	N
P72	43.15	UD	22.83	32.07	UD	UD	22.59	32.43	UD	UD	UD	25.15	N	N	N
P73	UD	UD	28.21	33.01	UD	UD	28.13	33.57	UD	UD	UD	25.95	N	N	N
P74	UD	UD	25.78	32.16	UD	UD	25.66	32.53	UD	UD	UD	24.71	N	N	N
P75	38.44	35.68	26.65	32.44	39.20	38.93	26.31	33.25	35.47	UD	UD	25.79	P	P	Inc
P76	22.69	22.62	25.77	32.01	23.04	23.42	25.12	32.39	21.91	22.55	22.77	26.69	P	P	P
P77	21.47	21.60	23.90	33.21	21.84	22.33	23.98	32.68	21.16	22.53	22.38	30.08	P	P	P
P78	UD	UD	24.49	32.73	UD	UD	24.37	33.07	UD	UD	UD	25.72	N	N	N
P79	UD	UD	27.14	33.85	UD	UD	27.06	35.00	UD	UD	UD	26.04	N	N	N
P80	UD	UD	22.78	32.70	UD	UD	22.89	33.24	UD	UD	UD	25.80	N	N	N
P81	UD	UD	23.01	32.61	UD	UD	22.74	32.79	UD	UD	UD	25.57	N	N	N
P82	UD	UD	26.99	31.79	UD	UD	26.84	32.72	UD	UD	UD	25.52	N	N	N
P83	UD	UD	31.29	35.55	UD	UD	31.42	35.57	UD	UD	UD	27.24	N	N	N
P84	UD	UD	22.18	31.85	UD	UD	21.99	32.82	UD	UD	UD	24.75	N	N	N
P85	UD	UD	24.37	32.50	UD	UD	24.14	33.25	UD	UD	UD	25.85	N	N	N
P86	UD	UD	23.23	31.79	UD	UD	23.15	32.62	UD	UD	UD	24.80	N	N	N
P87	UD	UD	23.10	31.79	44.55	UD	22.99	31.89	UD	UD	UD	24.76	N	N	N
P88	UD	UD	24.51	32.62	UD	UD	24.48	33.49	UD	UD	UD	25.17	N	N	N
P89	UD	UD	24.67	32.02	UD	UD	24.45	34.68	UD	UD	UD	25.17	N	N	N
P90	25.58	25.96	23.32	31.65	26.04	26.56	23.27	32.18	24.15	24.71	24.87	24.73	P	P	P
P91	UD	UD	20.27	31.55	UD	UD	20.30	31.207	UD	UD	UD	24.95	N	N	N
P92	17.51	16.25	20.36	29.33	17.24	16.79	20.49	31.68	17.28	16.97	17.10	27.18	P	P	P
P93	UD	UD	22.97	32.74	UD	UD	22.89	33.44	UD	UD	UD	25.60	N	N	N
P94	UD	UD	23.60	32.46	UD	UD	23.70	33.29	UD	UD	UD	25.16	N	N	N
P95	UD	UD	25.18	32.93	UD	UD	24.99	33.28	UD	UD	UD	26.64	N	N	N

	N1E-RP assay				N2E-RP assay				TaqPath assay				Conclusion		
Patient	**N1**	**E**	**RPP30**	**PhHV**	**N2**	**E**	**RPP30**	**PhHV**	**N**	**ORF1ab**	**S**	**MS2**	**N1E-RP**	**N2E-RP**	**TaqPath**
P96	UD	UD	23.53	33.50	UD	UD	23.31	34.08	UD	UD	UD	25.88	N	N	N
P97	UD	UD	25.64	31.92	UD	UD	25.09	31.82	UD	UD	UD	24.83	N	N	N
P98	21.50	20.39	23.62	31.84	21.29	20.90	23.20	32.92	20.73	20.43	21.33	25.97	P	P	P
P99	UD	UD	23.01	32.16	UD	UD	23.43	34.11	UD	UD	UD	27.60	N	N	N
P100	18.24	18.92	21.51	32.04	18.68	19.44	21.99	32.50	17.91	18.05	18.69	25.49	P	P	P
P101	UD	UD	23.77	32.02	UD	UD	24.05	32.62	UD	UD	UD	25.25	N	N	N
P102	UD	UD	24.71	30.80	UD	UD	24.59	31.29	UD	UD	UD	24.31	N	N	N
P103	UD	UD	23.61	32.64	UD	UD	23.55	32.82	UD	UD	UD	25.13	N	N	N
P104	UD	UD	23.12	31.92	UD	UD	22.77	32.44	UD	UD	UD	24.57	N	N	N
P105	24.75	25.23	25.61	31.03	25.26	25.85	25.33	31.82	25.95	26.11	26.42	24.74	P	P	P
P106	UD	UD	26.67	32.93	UD	UD	26.60	32.68	UD	UD	UD	25.36	N	N	N
P107	33.90	32.43	21.76	31.97	34.09	33.04	21.71	31.89	32.29	33.97	32.74	24.80	P	P	P
P108	UD	UD	27.70	32.01	UD	UD	27.35	33.17	UD	UD	UD	24.69	N	N	N
Controls															
-ve (extr)	UD	UD	UD	31.75	UD	UD	UD	32.77	UD	UD	UD	25.18	OK	OK	OK
-ve	UD	UD	UD	UD	UD	UD	UD	UD	UD	UD	UD	UD	OK	OK	OK
+ve	30.89	34.15	*	UD	30.35	34.49	*	UD	31.28	31.88	31.23	UD	OK	OK	OK

UD, undetermined; P, positive; N, negative; Inc, inconclusive
-ve (extr), negative control with viral transport medium after RNA isolation (does not contain SARS-CoV-2 or human material; does contain PhHV);
-ve, negative control containing water only (should not contain any RNA)
+ve, positive control with in vitro transcribed RNA (50 copies; contains SARS-CoV-2 target RNA, does not contain human or PhHV RNA)
* UD, but FAM-positive samples give ~5% signal bleed through into the JOE channel; this should be taken into account for samples without any true RPP30 (HEX) signal

Table S5 | Percentage of known SARS-CoV-2 genomic sequences with mutations in primer/probe binding sites for RdRp, M and S gene assays

Assay	Primer/probe	Percentage of strains with any mismatch/deletion*		Percentage of strains with mismatch in 5 most 3' nt*	
		Per primer/probe	Per assay**	Per primer	Per assay***
RdRp	RdRp_SARSr-F2	0.44%	100%	0.071%	0.078%
	RdRp_SARSr-P2	0.66%		(0.005%)	
	RdRp_SARSr-R1	100%		0.007%	
M gene	M-475-F	0.16%	1.11%	0.042%	0.045%
	M-507-P	0.87%		(0.857%)	
	M-574-R	0.08%		0.003%	
S gene	S-Gene-F	0.65%	1.90%	0.067%	0.375%
	S-Gene-P	0.74% (0.31%)*		(0.043%)	
	S-Gene-R	0.55%		0.308%	

High quality genome sequences analysed only (n=97,782).

* No genomes have deletions in primer/probe binding regions, with the exception of the S-gene probe, which has a 6 nt deletion in 0.31% of genome sequences. Presence of these changes does not necessarily impact on primer/probe performance. Mutations at the 3’ ends for the primer regions (here defined as the final 5 nt) are more likely to affect assay sensitivity.

** Mismatches/deletions in the primer/probe set used in single target assay

*** Mismatches in the forward and reverse primers only. For probes values are given between brackets for reference (in the “per primer” column).

Table S6 | Interpretation and suggested action based on N1E-RP or N2E-RP qRT-PCR results

SARS-CoV-2 targets	RPP30 Cq	Interpretation	Suggested action
No positives (UD, or Cq > 40)	High*	Inconclusive (possible negative), but poor sample	Repeat sampling
	Low*	Negative	Report negative
One weak positive (Cq 35-40)	High	Inconclusive; poor sample	Repeat sampling
	Low	Inconclusive	Perform different assay with different primers/probes and of equal or higher sensitivity
Two weak positives (Cq 35-40)	High	Positive; poor sample	Report positive
	Low	Likely (weak) positive	Report positive
One moderate positive (Cq 30-35)	High	Inconclusive, likely positive; poor sample	Perform different assay with different primers/probes and of equal or higher sensitivity (consider repeat sampling)
	Low	Inconclusive, possible positive	Perform different assay with different primers/probes and of equal or higher sensitivity
Two moderate positives (Cq 30-35)	High	Positive; poor sample, but does not affect conclusion	Report positive
	Low	Positive	Report positive
One strong positive (Cq < 30)	High	Inconclusive, likely positive; poor sample	Perform different assay with different primers/probes and of equal or higher sensitivity (consider repeat sampling)
	Low	Inconclusive, likely positive (second target may have mutations)	Perform different assay with different primers/probes and of equal or higher sensitivity to rule out false positive
Two strong positives (Cq < 30)	High	Positive; poor sample, but does not affect conclusion	Report positive
	Low	Positive	Report positive

High PhHV Cq values (>35; but depending on the exact amount used for spike-in; 2 to 3 cycles above the expected Cq is a good guide) indicate poor RNA isolation and/or presence of PCR inhibitors. Therefore, any negative (i.e. both SARS-CoV-2 targets not detected) or inconclusive samples (i.e. only one SARS-CoV-2 targets detected) should be interpreted in this context, and repeat sampling/testing must be performed. This has no impact on positive samples (both SARS-CoV-2 targets detected), which should still be reported as such.

* The precise RPP30 Cq cut-off value remains to be determined. This requires collection of a much larger amount of data, including repeat sampling of sufficient numbers of patients with varying RPP30 Cq values and initial negative test results. As an initial guide repeat sampling could be performed for any sample with RPP30 Cq >30. For any samples with RPP30 Cq values undetermined or >40, repeat sampling is essential, unless both SARS-CoV-2 targets are <40, in which case the test result is positive.

Supplementary Protocol 1: 4-plex SARS-CoV-2 RT-qPCR assay

Primers/probes

Dissolve primers and probes (Table P1; HPLC purified) in 10 mM Tris, 0.1 mM EDTA, pH 8.0 (IDTE Cat. No. 11-05-01-09, or similar) for 100 µM stocks. Prepare primer/probe mixes (Tables P2-P7), and store aliquots at -20°C. Working stocks can be stored at 4°C.

Table P1. Primer/Probe details for 4-plex assays

Target	Oligonucleotide ID	Sequence (5'-3')	PCR Product Size	Reference
SARS-CoV-2, E gene	E_Sarbeco_F1	ACAGGTACGTTAATAGTTAATAGCGT	113 bp	[1, 2]
	E_Sarbeco_R2	ATATTGCAGCAGTACGCACACA		
	TxRd_E_Sarbeco_P1*	CFR-610-ACACTAGCCATCCTTACTGCGCTTCG-BHQ2		
SARS-CoV-2, N gene	2019-nCoV_N1-F	GACCCCAAAATCAGCGAAAT	72 bp	[3]
	2019-nCoV_N1-R	TCTGGTTACTGCCAGTTGAATCTG		
	2019-nCoV_N1-P	FAM-ACCCCGCATTACGTTTGGTGGACC-BHQ1		
SARS-CoV-2, N gene	2019-nCoV_N2-F	TTACAAACATTGGCCGCAAA	67 bp	[3]
	2019-nCoV_N2-R	GCGCGACATTCCGAAGAA		
	2019-nCoV_N2-P	FAM-ACAATTTGCCCCCAGCGCTTCAG-BHQ1		
Human *RPP30*	Hs_RPP30-F	AGATTTGGACCTGCGAGCG	65 bp	[3]
	Hs_RPP30-R	GAGCGGCTGTCTCCACAAGT		
	HEX-Hs_RPP30-P	HEX–TTCTGACCTGAAGGCTCTGCGCG–BHQ1		
PhHV-1, Glycoprotein B	PhHV-F	GGGCGAATCACAGATTGAATC	89 bp	[4]
	PhHV-R**	GCGGTTCCAAACGTACCA(A)		
	Cy5-PhHV-P***	Quasar-670-TTTTTATGTGTCCGCCACCATCTGGATC-BHQ2		

* Probe named TxRd for simplicity, CAL Flour Red (CFR-610) has virtually identical properties to TexRed

** Reverse primer GCGGTTCCAAACGTACCA used for our work; GCGGTTCCAAACGTACCAA used in [4]; both should work equally

*** Probe named Cy5 for simplicity. Quasar 670 has virtually identical properties to Cy5

Primer/Probe Mixes

Table P2. 50x N1 (FAM) Primer/Probe Mix

Oligonucleotide	Stock Concentration (µM)	Concentration in 50x mix (µM)	Concentration in reaction (nM)	Volume (µL)
2019-nCoV_N1-F	100	25	500	50
2019-nCoV_N1-R	100	25	500	50
2019-nCoV_N1-P	100	6.25	125	12.5
Nuclease free water	-	-	-	87.5
Total				**200**

Table P3. 50x N2 (FAM) Primer/Probe Mix

Oligonucleotide	Stock Concentration (µM)	Concentration in 50x mix (µM)	Concentration in reaction (nM)	Volume (µL)
2019-nCoV_N2-F	100	25	500	50
2019-nCoV_N2-R	100	25	500	50
2019-nCoV_N2-P	100	6.25	125	12.5
Nuclease free water	-	-	-	87.5
Total				**200**

Table P4. 50x E gene (TexRed) Primer/Probe Mix

Oligonucleotide	Stock Concentration (µM)	Concentration in 50x mix (µM)	Concentration in reaction (nM)	Volume (µL)
E_Sarbeco_F1	100	20	400	40
E_Sarbeco_R2	100	20	400	40
TxRd_E_Sarbeco_P1	100	10	200	20
Nuclease free water	-	-	-	100
Total				**200**

Table P5. 50x *RPP30* (HEX) Primer/Probe Mix

Oligonucleotide	Stock Concentration (µM)	Concentration in 50x mix (µM)	Concentration in reaction (nM)	Volume (µL)
Hs_RPP30-F	100	25	500	50
Hs_RPP30-R	100	25	500	50
HEX-Hs_RPP30-P	100	6.25	125	12.5
Nuclease free water	-	-	-	87.5
Total				**200**

Table P6. 50x PhHV (Cy5) Primer/Probe Mix

Oligonucleotide	Stock Concentration (µM)	Concentration in 50x mix (µM)	Concentration in reaction (nM)	Volume (µL)
PhHV-F	100	15	300	30
PhHV-R	100	15	300	30
Cy5-PhHV-P	100	5	100	10
Nuclease free water	-	-	-	130
Total				**200**

Table P7. 12.5x 4-plex Primer/Probe Mix (for 100 reactions)

	Stock	Probe Concentration in 12.5x mix (µM)	Probe Concentration in reaction (nM)	Volume (µL)
N1 or N2 mix (FAM)	50x	1.56	125	50
E mix (TxRed)	50x	2.5	200	50
RPP30 mix (HEX)	50x	1.56	125	50
PhHV mix (Cy5)	50x	1.25	100	50
Total				**200**

RT-qPCR

Any Real-Time qPCR machine that can detect the four different channels and has been calibrated for the appropriate fluorophores can be used. We use the Applied Biosystems™ 7500 Fast Real-Time PCR Systems (channels FAM, JOE, TEXAS RED and CY5) and 7500 Software v2.3, MicroAmp Fast Optical 0.1mL 96-well reaction plates (Cat. No. 4346906) and Optical Adhesive film (Cat. No. 4311971). We performed all RT-qPCRs with Takara One Step PrimeScript™ III RT-qPCR kit (Cat. No. RR600B). Other One-Step mixes are available, but may require slightly different reaction conditions and may change sensitivity of SARS-CoV-2 detection.

N1E-RP and N2E-RP 4-plex assay

Master Mix (20 µl per reaction), assemble on ice

H_2O (RNase free)	5.5 µl	for 100x	550 µl
2x reaction mix	12.5 µl		1250 µl
12.5x primer/probe mix	2 µl		200 µl
Mix with template RNA	5 µl		

Spin down before transferring to PCR machine

PCR program

52°C	5 min (reverse transcription)	
95°C	10 s (RT inactivation/denaturation)	
45 cycles of	95°C	3 s (denaturation)
	60°C	30 s (amplification & detection)

Controls

Add the viral spike-in control to the lysis buffer master mix before sample inactivation.

[For our assays, we used 25 µl of culture supernatant containing PhHV particles to 25 ml of lysis buffer. This amount was previously shown to give a Cq value of ~33.]

For each plate, include the following controls:

H10, negative extraction control, VTM extracted;

H11, non-extraction negative control, water only;

H12, 50 copies of positive control RNA (see below).

Positive control RNA

Positive control RNAs generated by in vitro transcription (IVT) were provided by:

- Sylvie Behillil (Institut Pasteur, Paris, France): mix of E gene and RdRp (the latter is not the same as the Corman et al (2020) RdRp template) [1-3] at 10^9 copies/µl.

- Christine Tait-Burkard (Roslin Institute, Edinburgh, UK): RdRp [1, 2], N1/N3 and N2 [3]. Three individual IVT RNAs at known concentrations (ng/µl) were provided; molecular weights used to determine the concentrations in copies/µl and 10^9 copies/µl prepared for each RNA.

Prepare all stocks and dilutions in Eppendorf DNA LoBind tubes (Cat. No. 10051232).

1. Prepare an equimolar mix of all RNAs at 2.5 x 10^8 copies/µl. Store aliquots of this solution at -80°C.

2. Prepare 10^4 copies/µl positive RNA controls and store 5 µl aliquots at -80°C for single use per plate. Mix 5µl of 2.5 x 10^8 copies/µl with 620 µl of water to give 2 x 10^6 copies/µl. Dilute this 20 µl plus 180 µl water giving a 2 x 10^5 copies/µl solution, and 20 µl plus 380 µl giving 10^4 copies/µl.

3. For each plate, a 25 copies/µl solution is made by diluting the 10^4 copies/µl solution by mixing:

2 µl with 98 µl water, then

12.5 µl of this with 87.5 µl water

Of this 25 copies/µl solution, 2 µl is added to well H12 along with 3 µl of water, to give the 50 copy positive control on each plate.

Supplementary Protocol 2: Viral nucleic acid isolation

In principle, the buffers and solution below can replace those of the equivalent buffers in the Omega Mag-Bind Viral DNA/RNA 96 Kit (Cat. No. M6246). Lysis and wash buffers can either be replaced with guanidine thiocyanate (GnSCN) or guanidine hydrochloride (GnHCl) containing solutions, depending on reagent availability. In our preliminary tests, all performed equally well (data not shown). All lysis buffers (Omega TNA, GnSCN Lysis Buffer, GnHCl Lysis Buffer, each with/without isopropanol) were shown to inactivate coronavirus after 15 min incubation (Fig P1). Briefly, to determine whether lysis buffers inactivate coronaviruses, 200 µl CoV 229E-GFP [5, 6] stock ($9.6x10^5$ pfu/ml in DMEM, 10% FCS, 1% NEAA) was mixed with lysis buffer at the recommended ratio (240 µl lysis buffer without isopropanol or 520 µl lysis buffer with isopropanol, i.e. 240 µl buffer and 280 µl isopropanol). For positive infection controls, virus was mixed with 240 or 520 µl medium. All mixes were inverted 8 times and incubated at room temperature for 15 min. Cytotoxic components were then removed by centrifugation at 4°C using Microcon filter columns (Millipore; 30 kDa cut-off), and two 0.5 ml PBS washes, similar to previously described methods [7, 8]. Remaining virus particles were then resuspended in 200 µl DMEM and 50 µl of a 1/100 dilution added to HUH7 cells (a cell line permissive to infection by CoV 229E). Cells were seeded the previous day at $1.8x10^4$/well in a black 96-well plate (Corning), and were at ~80% confluence for infection. Cultures were monitored daily for cell viability, cytopathic effects and GFP expression using microscopy. No significant cell death was observed for any of the samples. Relative fluorescence was measured using a Clariostar BMG Plate Reader at 72 h, with fluorescence for a non-infected control set to zero. No fluorescence was observed for any of the lysis buffer treated samples (Fig P1), and fluorescence microscopy confirmed the absence of GFP positive cells (data not shown), consistent with complete viral inactivation.

In our preliminary tests, we used the March 2020 version of the protocol provided with the Omega Mag-Bind Viral DNA/RNA 96 Kit to test viral nucleic acid isolation with our own solutions and reagents (see below). We used the Mag-Bind Particles CNR from the Omega kit, and although we have not yet tested this, we expect that these can be replaced by SeraSil-Mag silica beads (Cytiva, cat No. 29357375). The March 2020 protocol is different from the April 2020 Supplementary Protocol provided by Omega. The latter was used in combination with original Omega kit components for all other work presented in our manuscript. We do not see any reasons why our solutions would not work equally well with the April 2020 version of the protocol, but have not tested this. All purifications were carried out using a KingFisher Flex robot (Cat. No. 5400610), KingFisher Deep well plates (Cat. No. 95040450), KingFisher Flex 96 Deep-Well Tip Combs (Cat. No.

A43074) and KingFisher 96 microplates (Cat. No. 97002540). Alternative robots could be used; and manual purifications are also possible.



Figure P1 | Inactivation of coronavirus CoV-229E by Omega TNA, and GnSCN and GnHCl lysis buffers. CoV 229E-GFP was mixed with lysis buffer (- or + isopropanol) as described and then used to infect HUH7 cells. After 72 h of infection, GFP fluorescence (indicating infected cells) was measured. Negative (Neg) control, no infection; positive control (Pos1 and 2), virus mixed with medium instead of lysis buffer. Fluorescence units (RFU) are expressed relative to background (negative control fluorescence set to 0). Solid lines indicate the mean for n = 2 independent experiments.

Protocol in brief (tested with home-made solutions; based on Omega March 2020 protocol)

1. Per sample, prepare 528 µl master mix: 240 µl lysis buffer, 8 µl carrier RNA (1 µg/µl) and 280 µl isopropanol
2. Add 200 µl of patient sample in VTM, mix thoroughly; incubate for >15 min
3. Add 20 µl of 1:1 mix of Magnetic bead suspension and Proteinase K solution (40 µg/µl). KingFisher Flex, loop though 3 times: 2 min fast mix, 30 s half mix, 30 s bottom mix
4. Employ magnetic separation (Collect beads, 3x10 s)
5. Wash beads with 400 µL VHB wash buffer (Release beads, 3 min fast mix, collect beads 3x5 s)
6. Wash beads with 500 µL SPR Wash buffer (Release beads, 2 min fast mix, collect beads 3x5 s)
7. Wash beads with 500 µL SPR Wash buffer (Release beads, 2 min fast mix, collect beads 3x5 s)
8. Air dry magnetic beads (10 min, above well)
9. Elute nucleic acids in 50 µl nuclease-free water (Release beads, 5 min medium mix, collect beads 3x10 s)

Protocol in brief (not tested with home-made solutions; based on Omega April 2020 protocol)

1. Per sample, mix 240 µl lysis buffer and 1 µl carrier RNA (1 µg/µl)
2. Add 200 µl of patient sample in VTM, mix thoroughly; incubate for >15 min
3. Add isopropanol bead mix (280 µl isopropanol and 2 µl magnetic beads). KingFisher Flex, loop though 3 times: 2 min fast mix, 30 s half mix, 30 s bottom mix
4. Employ magnetic separation (Collect beads, 3x10 s)
5. Wash beads with 350 µL VHB wash buffer (Release beads, 3 min fast mix, collect beads 3x5 s)
6. Wash beads with 350 µL SPR Wash buffer (Release beads, 2 min fast mix, collect beads 3x5 s)
7. Wash beads with 350 µL SPR Wash buffer (Release beads, 2 min fast mix, collect beads 3x5 s)
8. Air dry magnetic beads (10 min, above well)
9. Elute nucleic acids in 50 µl nuclease-free water (Release beads, 5 min medium mix, collect beads 3x10 s)

Reagents

Guanidine thiocyanate based

GnSCN Lysis Buffer (TNA Lysis buffer equivalent)

	Amount for 1 L	Concentration
Guanidine thiocyanate	473 g	4 M
Sarkosyl (sodium lauroyl sarcosinate)	20 g	2%
1 M Tris-HCl pH 7.5	50 ml	50 mM
0.5 M EDTA pH 8.0	20 ml	10 mM
β-mercaptoethanol	10 ml	1%

GnSCN Wash buffer 1 (VHB Wash buffer equivalent)

	Amount for 1 L	Concentration
Guanidine thiocyanate	118 g	1 M
1 M Sodium citrate pH 7*	10 ml	10 mM
Ethanol	560 ml	56%

*to set pH, add 10 ml 1 M HCl for every 500 ml 1 M Sodium citrate.

Guanidine hydrochloride based

GnHCl Lysis Buffer (TNA Lysis buffer equivalent)

	Amount for 1 L	Concentration
Guanidine hydrochloride	573 g	6 M
Sarkosyl (sodium lauroyl sarcosinate)	20 g	2%
1 M Tris-HCl pH 7.5	50 ml	50 mM
0.5 M EDTA pH 8.0	20 ml	10 mM
β-mercaptoethanol	10 ml	1%

GnHCl Wash Buffer 1 (VHB Wash buffer equivalent)

	Amount for 1 L	Concentration
Guanidine hydrochloride	107 g	1.25 M
1 M Sodium citrate pH 7*	10 ml	10 mM
Ethanol	560 ml	56%

*to set pH, add 10 ml 1 M HCl for every 500 ml 1 M Sodium citrate.

SPR Wash buffer 2 equivalent

80% Ethanol

Proteinase K (PCR grade; e.g. Roche Cat. No. 03115801001)

Dissolve in 10 mM Tris pH 8.0, 1 mM EDTA at 40 mg/ml

Store aliquots at -20°C

Carrier RNA (e.g. yeast tRNA, Roche Cat. No. 10109509001)

Dissolve in 10 mM Tris pH 8.0, 1 mM EDTA at 1 mg/ml

Store aliquots at -20°C

Supplementary references

1. Corman VM, et al. Diagnostic detection of 2019-nCoV by real-time RT-PCR, protocol v2 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf.
2. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3). Epub 2020/01/30. doi: 10.2807/1560-7917.ES.2020.25.3.2000045. PubMed PMID: 31992387; PubMed Central PMCID: PMCPMC6988269.
3. WHO in-house assays COVID-19 RT-qPCR 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/whoinhouseassays.pdf?sfvrsn=de3a76aa_2.
4. Stranska R, Schuurman R, de Vos M, van Loon AM. Routine use of a highly automated and internally controlled real-time PCR assay for the diagnosis of herpes simplex and varicella-zoster virus infections. J Clin Virol. 2004;30(1):39-44. Epub 2004/04/10. doi: 10.1016/j.jcv.2003.08.006. PubMed PMID: 15072752.
5. Cervantes-Barragan L, Zust R, Maier R, Sierro S, Janda J, Levy F, et al. Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity. mBio. 2010;1(4). Epub 2010/09/17. doi: 10.1128/mBio.00171-10. PubMed PMID: 20844609; PubMed Central PMCID: PMCPMC2939679.
6. Thiel V, Siddell SG. Reverse genetics of coronaviruses using vaccinia virus vectors. Curr Top Microbiol Immunol. 2005;287:199-227. Epub 2004/12/22. doi: 10.1007/3-540-26765-4_7. PubMed PMID: 15609513.
7. Burton JE, Easterbrook L, Pitman J, Anderson D, Roddy S, Bailey D, et al. The effect of a non-denaturing detergent and a guanidinium-based inactivation agent on the viability of Ebola virus in mock clinical serum samples. J Virol Methods. 2017;250:34-40. Epub 2017/09/25. doi: 10.1016/j.jviromet.2017.09.020. PubMed PMID: 28941617.
8. Pastorino B, Touret F, Gilles M, de Lamballerie X, Charrel RN. Heat Inactivation of Different Types of SARS-CoV-2 Samples: What Protocols for Biosafety, Molecular Detection and Serological Diagnostics? Viruses. 2020;12(7). Epub 2020/07/11. doi: 10.3390/v12070735. PubMed PMID: 32646015; PubMed Central PMCID: PMCPMC7412566.